**Title:** Glymphatic flow resistance in humans measured by multifrequency impedance dispersion

**Authors:** Paul Dagum, MD, PhD[1]; Laurent Giovangrandi, PhD[1]; Swati Rane Levendovszky,

PhD[2]; Jake J. Winebaum[1]; Tarandeep Singh, MS[1]; Yeilim Cho, MD[3]; Robert M. Kaplan, PhD[4];

Michael S. Jaffee, MD[5]; Miranda M. Lim, MD, PhD[6,7,8]; Carla Vandeweerd[9,10], PhD; Jeffrey J.

Iliff, PhD[3,11,12]

**Affiliations:** [1]Applied Cognition Inc, Redwood City, CA; [2]Department of Radiology, University of

Washington School of Medicine, Seattle, WA; [3]VISN 20 NW Mental Illness Research, Education

and Clinical Center, VA Puget Sound Healthcare System, Seattle, WA; [4]Clinical Excellence

Research Center, Stanford University School of Medicine, Stanford, CA; [5] Department of

Neurology, University of Florida Health, Gainesville, FL; [6]VISN 20 Northwest Mental Illness

Research, Education and Clinical Center (MIRECC), VA Portland Health Care System,

Portland, OR; [7]Neurology Service, Research Service, VA Portland Health Care System,

Portland, OR; [8]Department of Neurology, Oregon Alzheimer's Disease Research Center,

Oregon Health & Science University, Portland, OR; [9]University of Florida Health Precision

Health Research Center, Clinical and Translational Science Institute, University of Florida,

Gainesville, FL; [10]Health Outcomes and Biomedical Informatics, College of Medicine, University

of Florida, Gainesville, FL; [11]Department of Psychiatry and Behavioral Science, University of

Washington School of Medicine, Seattle, WA; [12]Department of Neurology, University of

Washington School of Medicine, Seattle, WA;

**Corresponding Author:**
Paul Dagum, MD, PhD
Applied Cognition Inc
1629 Main St.
Redwood City, CA 94063
paul@appliedcognition.com
Ph: (415) 378-5456
30

**ABSTRACT**

Glymphatic function in animal models supports the clearance of brain proteins whose mis-

aggregation is implicated in neurodegenerative conditions including Alzheimer's and

Parkinson's disease. The measurement of glymphatic function in the human brain has been

elusive, limiting its potential in translational research. Here we described a non-invasive

multimodal device for the first-in-human continuous measurement of sleep-active glymphatic

flow resistance using repeated electrical impedance spectroscopy measurements through two

separate clinical validation studies. Device measurements successfully (i) paralleled sleep-

associated changes in extracellular volume that regulate glymphatic function, (ii) replicated

preclinical findings showing glymphatic function is increased with increasing sleep EEG delta

power, and is decreased with increasing sleep EEG beta power and heart rate, and (iii)

predicted glymphatic solute exchange measured by contrast-enhanced MRI. The present

investigational device permits the continuous and time-resolved assessment of glymphatic flow

resistance in naturalistic settings necessary to determine the contribution of glymphatic

impairment to risk and progression of Alzheimer's disease, and to enable target-engagement

studies that modulate glymphatic function in humans.

**Words 11957**

**Without methods 5467**

## INTRODUCTION

The glymphatic system is a brain-wide network of perivascular pathways along which the cerebrospinal fluid (CSF) surrounding the brain exchanges with brain interstitial fluid, supporting nutrient distribution and waste clearance (**Figure 1a-b**). In animal models, glymphatic function supports the clearance of amyloid beta[1,2], tau[3-5], and alpha synuclein[6,7], whose mis-aggregation is implicated in the pathogenesis of neurodegenerative conditions including Alzheimer's and Parkinson's disease. Glymphatic function is further postulated to be a mechanism for volume transmission of the neurotransmitters acetylcholine, serotonin and norepinephrine, and of neurohormones regulating brain-body homeostasis[8]. While this system is foundational to brain health and disease, measurement of glymphatic function in the human brain, principally by magnetic resonance imaging (MRI), is conducted in only a handful of academic neuroimaging centers[9]. Without a consistent, reproducible and accessible way of measuring this important neurobiology in humans, the promise of developing therapeutic interventions that target glymphatic function to treat and prevent neurological and psychiatric diseases remains elusive.

Studies in rodents have demonstrated that glymphatic function is more rapid during sleep compared to the awake state[2,10]. During periods of wakefulness, the interstitial space is narrow and tortuous, forming a high-resistance pathway that suppresses glymphatic flow, while during sleep fluid shifts from the intracellular compartment into the extracellular (interstitial) space, widening these pathways, and enhancing glymphatic function by ~60% (**Figure 1c-d**). Measuring glymphatic function across a range of physiological conditions demonstrated that faster glymphatic exchange is associated with increased electroencephalogram (EEG) delta band power, decreased EEG beta power, and reduced heart rate[11]. Studies utilizing contrast-enhanced (CE)-MRI to measure solute exchange between the CSF and brain interstitial compartments have confirmed in human participants more rapid glymphatic function during sleep[12], although the poor temporal resolution of this approach[13-15] has not permitted the

relationship between EEG or cardiovascular features and glymphatic function to be defined in

the human brain.

Electrical impedance spectroscopy (EIS) is widely used in medicine for body composition

analysis and for monitoring cellular changes in settings including tumors and edema[16-19]. When

alternating current is injected into tissue, at low frequencies the voltage drop depends primarily

on the resistive pathway of the extracellular (interstitial) fluid, while at high frequencies cell

membranes behave like capacitors allowing current to also pass relatively freely through the

intracellular space (**Figure 1c-e**). This frequency dependence is the β-dielectric dispersion of

the underlying tissue and its repeated measurement permits the detection of shifts in the

extracellular and intracellular distribution of water within tissue[17,20].

We propose that the biophysics of EIS can be leveraged to measure the fluid shift that occurs

with changes in sleep-active glymphatic function. Because intracranial volume is constant, any

change in this frequency dependence across repeated EIS measures reflects changes in the

resistance of the extracellular space, which is inversely proportional to the extracellular fluid

volume (**Figure 1c-e**). Within the brain, the extracellular compartment includes the brain

interstitial space (~16% of total volume) and a combination of CSF (~10%) and blood plasma

(~6%)[21]. Small diurnal fluctuations occur in blood volume and in the CSF compartments,

however these changes are small and offset one another across physiological states[22,23]. In

contrast, sleep-wake differences in glymphatic function are associated with much larger shifts in

the intracellular and particularly interstitial volumes[2]. Thus, sleep-wake changes in EIS

measures will be sensitized to changes in brain intracellular and interstitial volume, and EIS-

based measures of parenchymal resistance ($R_P$) may represent a novel approach to track

sleep-active glymphatic function.

**Figure 1. Detection of sleep-wake changes in glymphatic flow resistance by impedance spectroscopy. a**, Glymphatic function involves the influx of cerebrospinal fluid (CSF) influx along perivascular spaces (PVSs) surrounding penetrating arteries (center). Glymphatic flow is driven by arterial pulsations and vasomotor oscillations (right). Astrocytic endfoot processes create the barrier between the PVS and the brain parenchyma, with gaps allowing CSF to exchange through the brain interstitial space. The endfoot processes are studded with perivascular aquaporin-4 water channels that also enable water to move into the astrocytes and out to the interstitial space. **b,** Data from physiological studies in rodents suggest that glymphatic function is increased in conditions of reduced heart rate, increased vasomotor pulsations, reduced EEG beta power, and increased EEG delta power (Hablitz et al. 2019). **c,** The interstitial space is dynamically regulated. Under conditions of low EEG delta power and high EEG beta power common to the awake state, it is narrow and tortuous, forming a high-resistance pathway that suppresses glymphatic function. When alternating current is injected into the brain parenchyma, at low frequencies the current cannot penetrate the capacitive cell membranes and its propagation depends primarily on the resistive pathway of the interstitial fluid. At high current frequencies, the current readily penetrates the capacitive cell membranes and its propagation depends on the resistance of the total tissue volume. This frequency difference is the β-dielectric dispersion of the underlying tissue. If the intracranial volume is constant, a change in the dielectric dispersion reflects a change in the low-frequency resistance pathway of the interstitial fluid. **d,** Under high EEG delta power and low EEG beta power common to the sleep state, fluid shifts from the intracellular compartment into the interstitial space, enhancing glymphatic function by ~60% in rodent studies (Xie et al. 2013). This widening of interstitial pathways reduces the current resistance at low-frequencies which reduces the measured dielectric dispersion. **e**, An impedance-frequency graph shows the change in dielectric dispersion between the two sleep/wake EEG states. The change in glymphatic flow resistance between these two states is inversely proportional to the relative change in the dielectric dispersion. **f,** Contrast-enhanced MRI following intravenous gadolinium-based contrast agent (GBCA) injection shows vascular regions that enhance immediately (t=30 min) upon GBCA injection (red), and CSF and brain parenchymal regions that enhance late (t=3 hrs) after leakage of GBCA first into the CSF and thence into the brain interstitium (green). A given MRI voxel includes GBCA within the blood, CSF and brain interstitial fluid compartments.

We developed a wearable investigational device (**Figure 2a-f**) that overcomes several technical

challenges surrounding the implementation of EIS as a measure of glymphatic flow resistance.

To define the dynamic relationship between $R_P$, sleep EEG features, and cardiovascular

parameters through the course of an overnight period, EIS measurements must be made with

high accuracy and temporal resolution. The investigational device performs measurements at

frequencies between 1kHz and 256kHz and has a ~3% measurement error in $R_P$

(**Supplemental 4)** enabling it to detect small changes in dispersion between repeated

measures. It is important to ensure that device measurements are not affected by changes in

electrode impedances that can occur over time, including those caused by the effects of motion

on the electrode-skin interface. A non-traditional four-electrode impedance configuration was

used with multiple excitation and sense configurations in combination with low-impedance, non-

polarizable electrodes. This ensured high-fidelity measurements including at low frequencies

due to the reduced sensitivity to motion artifacts, low noise, and stability of the skin-gel-

electrode interface. A signal processing approach enabled identification of signal from noise

using the real and imaginary parts of the impedance to establish if the measured response is

related to the excitation signal or has been distorted by artifact. The device further integrated

shielded cables to reduce effects of electromagnetic interferences, both external and internal to

the device, and the design minimized stray capacitances affecting higher frequencies. The

device is described in more detail in **Methods** and **Supplemental Information** including

**Supplemental Figure 2, Supplemental Figure 3** and **Supplemental Tables 7 – 12**. We note

that glymphatic flow is determined by the parenchymal resistance to flow and the motive force

driving CSF along the perivascular spaces (PVS) into the interstitial compartment. The

resistance measured by the device is transcranial with a high temporal resolution of changes in

global intracellular to interstitial fluid shifts.

**Figure 2. Technical schematic of investigational device and its output signals.** Data for
this study was acquired with a non-invasive multimodal skin-interfaced wireless device for
continuous measurement of brain parenchymal resistance using repeated electrical impedance
spectroscopy EIS time-multiplexed with EEG and cardiovascular measurements. EEG
differential measurements were made between the two in-ear electrodes and a left mastoid was
used to drive the common mode. These electrodes were shared with the EIS and the two
measurements were time-multiplexed with a pair of analog multiplexers that decoupled EEG
and EIS. The transcranial multi-frequency alternating current injections created an electric field
through the brain and orthogonal equipotential surfaces. **a**, Each in-ear electronics housed PPG
and IMU sensors. **b**, Data from the sensors were stored on the device's FLASH memory and
transferred via a USB port to a cloud signal processing pipeline for offline analysis. Data from a
participant visit is shown, which includes the device EEG periodogram and hypnogram. **c**, The
EIS resistance and reactance frequency plots for this participant reveal an approximate 2000
mOhm change in the dielectric dispersion during the sleep visit. **d**, The IPG respiratory and
cardiac impedance variations are 120 mΩ and 50 mΩ, respectively. **e**, Cardiac ejection of blood
is detected by the in-ear IMUs in the ballistocardiogram. The J peak of the ballistocardiogram
marks the aortic valve opening. **f**, Time delay between the ballistocardiogram and in-ear PPG
measures the pulse-transit time (PTT) to the that ear.

**RESULTS**

Data were acquired using the investigational medical device developed by Applied Cognition

Inc[24,25]. Transcranial impedance dispersion is estimated from each EIS measure using a

dielectric relaxation model. In addition to EIS measurements, the device measures EEG,

photoplethysmogram (PPG), impedance plethysmogram (IPG) and head motion (**Figure 2a-f**).

We propose that the change in transcranial impedance dispersion, which we will henceforth

term parenchymal resistance $R_P$ ($R_P = R_0 - R_\infty$), reflects shifts in brain intracellular and

interstitial compartment fluid volumes that underlie changes in glymphatic function (**Figure 1c-**

**e**). **Supplemental 3** contains an intuitive justification of the physiological connection between

EIS change and changes in glymphatic function. To test this, we evaluated whether $R_P$

measured with this device in human participants aligned with the central features of glymphatic

function described in rodent models[2,11].

***Study Design***

We conducted two clinical studies (denoted as "Benchmarking Study" and "Replication Study")

to validate the performance of the device's $R_P$ measure as a surrogate of glymphatic flow

resistance during sleep and wake (**Figure 3**, top). Both studies were cross-over trials where

participants wearing the investigational device were subjected to one night of natural sleep and

one night spent awake, separated by two or more weeks. The Benchmarking Study was

conducted in The Villages® community, an active-lifestyle senior living community in Central

Florida where the University of Florida maintains a satellite academic research center, The

University of Florida Health Precision Health Research Center (UF Health PHRC). The

Benchmarking Study was designed to define the effect of sleep on overnight $R_P$ measurements,

as well as the relationship between $R_P$ and glymphatic function. It included overnight device

recordings, overnight gold-standard polysomnography (PSG), and morning contrast-enhanced

magnetic resonance imaging (CE-MRI) following intravenous gadolinium-based contrast agent

(GBCA) administration as a measure of glymphatic function. During the morning period,

following pre-contrast MRI scanning, GBCA injection, and immediate post-contrast MRI

scanning (totaling 2.5 hours spent awake), participants that were sleep deprived overnight were

provided a 1.5 hr sleep opportunity prior to the final MRI scan, while those that slept normally

overnight were kept awake during the 1.5 hr period (**Figure 3**, top). We evaluated whether, as

predicted from prior rodent studies on the sleep-modulation of glymphatic function[2,11], **a)** $R_P$ is

reduced in sleeping compared to awake participants, **b)** whether reduced $R_P$ is associated with

more rapid CSF-brain interstitial solute exchange measured by CE-MRI, **c)** whether $R_P$ is

associated with increasing sleep EEG delta power and decreasing sleep EEG beta power, and

**d)** whether reduced $R_P$ is associated with decreasing heart rate. The Replication Study

conducted at the University of Washington did not include overnight PSG or morning CE-MRI

and had as a primary outcome confirming the effect of sleep state on device-measured $R_P$, and

secondary outcomes confirming the associations between $R_P$ and sleep stages, heart rate, and

EEG spectral band power. As noted in the detailed study description in the Methods section,

these studies also evaluated novel non-contrast MRI measures of glymphatic function, sleep-

sensitive changes in cognitive function, and sleep-sensitive changes in plasma Alzheimer's

disease biomarkers across a range of physiological sleep conditions. Those findings will be

reported elsewhere.

**Inclusion and Exclusion Criteria**

All studies were performed between October 2022 – June 2023 and were reviewed and

approved by University of Florida Institutional Review Board (IRB No. 202201364,

Benchmarking Study) and Western Institutional Review Board (IRB No. 20225818, Replication

Study). The studies have been registered at ClinicalTrials.gov

(https://clinicaltrials.gov/study/NCT06222385 and https://clinicaltrials.gov/study/NCT06060054 ).

Written informed consent was obtained from all study participants during a screening visit, prior

**Figure 3. Study schematic and CONSORT diagram for Benchmarking Study and Replication Study. a**, The Benchmarking Study conducted at The Villages® was designed to define the relationship between parenchymal resistance ($R_P$) and glymphatic function. Reported here are the overnight and morning device recordings, overnight and morning gold-standard polysomnography (PSG), and morning contrast-enhanced magnetic resonance imaging (CE-MRI) following intravenous gadolinium-based contrast agent (GBCA) administration as a measure of glymphatic function. Primary and secondary outcome data not reported here included blood analysis of amyloid β and tau levels, cognitive assessment, and non-contrast MRI. **b**, The Replication Study conducted at the University of Washington had a primary outcome of confirming the effect of sleep state on device-measured $R_P$, and secondary outcomes of confirming the associations between $R_P$ and sleep stages, heart rate, and EEG spectral band power. The Replication Study also included secondary outcomes on blood analyses for amyloid β and tau levels, cognitive assessment and non-contrast MRI. **c**, The Benchmarking Study enrolled 34 participants of which 30 completed both visits. Three were censored due to changes in device data collection and sensor locations. One withdrew following the first MRI scan. Of the 30 that completed the study, 5 overnight sleep visits and 8 overnight wake visits failed the data quality control (QC) criteria to provide sufficient artifact free data to yield results. This resulted in 25 sleep and 22 wake device, PSG and MRI complete data sets. Of these, 20 sleep and 21 wake device participants had complete data from both the overnight and morning sleep/wake periods. The Replication Study enrolled 14 participants. All 14 completed the study, of which 3 wake visits failed the data QC criteria and no sleep visit failed. (sleep op, sleep opportunity)

to any study activities. Studies were carried out in accordance with the principles of the Belmont

Report. The Benchmarking Study enrolled 34 healthy participants 56-66 years of age. The

Replication Study enrolled 14 healthy participants 49-63 years of age. Participants were

excluded if they had cognitive impairment or clinical depression. Cognitive impairment was

assessed using the Montreal Cognitive Assessment[26] (MoCA, 28.1 +/- 1.2; range 26, 30) and

depression was evaluated using the 15-item Geriatric Depression Scale[27] (GDS, 0.7 +/- 1.1;

range 0, 4). Participants with a self-reported history of diabetes, hypertension, coronary artery

disease, pulmonary disease, neurological disease, depression or anxiety were also excluded

from the study, as were participants planning travel to alternate time zones within two weeks of

study participation. Participant demographics, MoCA and GDS scores are listed for each study,

and for the combined dataset in **Supplemental Table 1**.

A Consolidated Standards of Reporting Trials (CONSORT) diagram for the Benchmarking Study

and Replication Study is provided in **Figure 3** (bottom). Within the Benchmarking Study, the first

three participants were removed from analysis because of a design change in the

investigational device sensor positions. One participant was unable to complete the first MRI

session and withdrew from the study. Of the remaining 30 participants ($61.8 \pm 2.7$ years of age;

14 female, 16 male) that completed the Benchmarking Study, five overnight sleep studies and

eight overnight wake studies failed data quality control due to excessive artifacts in the

recordings, leaving 25 overnight sleep studies and 22 overnight wake studies in the

Benchmarking Study with complete device, PSG and MRI data. Excessive movement artifacts

during the morning recording periods resulted in the exclusion of data from five additional

morning wake and one additional morning sleep opportunity periods, leaving 20 overnight

sleep/morning wake and 21 overnight wake/morning sleep opportunity datasets with complete

overnight and morning data. All participants enrolled in the Replication Study ($55.6 \pm 4.6$ years

of age; 7 female, 7 male) completed the protocol. All overnight sleep data were usable, but

three overnight wake studies were removed, two because of excessive artifact and one because

of non-compliance with the wake protocol. The higher number of quality control failures in the

Benchmarking Study was largely due to the physical challenges caused by simultaneous data

acquisition from both PSG and investigational device on the same night. Note that when the

investigational device was used in the absence of PSG in the Replication Study, quality control

failures were less frequent and restricted to motion artifacts in the awake condition.

***Assessment of sleep and wake changes in parenchymal resistance***

Study participants underwent one night of normal sleep and one night of sleep deprivation

separated by 2-4 weeks. Sleep/wake or wake/sleep visit order was determined by random

assignment following informed consent. In the Benchmarking Study, sleep and wake status was

confirmed by PSG with anticipated differences in rapid eye movement (REM), and non-REM

(NREM: N1, N2, N3) sleep stages observed between sleep and wake conditions. Similar

differences were observed in the Replication Study, in which investigational device-based EEG

was used to evaluate sleep parameters. EEG was assessed with the investigational device in

both the Benchmarking and Replication Studies; these measures were used when combining

EEG parameters between both studies. Averaged hypnograms showing sleep stage distribution

throughout the overnight sleep period for the Benchmarking and Replication Studies are shown

in **Figure 4a-b** (top), respectively. The averaged hypnogram for the overnight and morning

periods for the Benchmarking study participants with complete data during both periods is

shown in **Figure 4c** (left)**.**

During the overnight period $R_P$ was continuously monitored. The results from the Benchmarking

Study are provided in **Figure 4a** (bottom), which depicts the mean and standard errors of

overnight $R_P$. Each participant's $R_P$ was normalized to the $R_P$ at onset of the observation period,

and linear interpolation was used for missing $R_P$ values within each participant. Compared to the

wake condition, overall $R_P$ during sleep was reduced by 8% (Wake 1.00 ± 0.06, Sleep 0.92 ±

0.06, T-test $p < 0.001$). When evaluated through the course of the overnight period, the $R_P$

during the wake period remained largely constant. In contrast, during the sleep period the mean

$R_P$ decreased monotonically, reaching at the end of the sleep period a nadir ~20% lower than at

onset or under the awake condition. Similar results were observed the Replication Study

(**Figure 4b**, bottom). Within the Benchmarking study, participants that were sleep deprived

overnight received a 1.5 hr sleep opportunity in the morning. Over this period, $R_P$ began at a

higher value (resulting from overnight sleep deprivation) but declined over the 1.5 hr sleep

opportunity (**Figure 4c**, right). Among participants that slept overnight but were kept awake in

the morning, $R_P$ during the morning period began at a low value (resulting from overnight sleep)

but increased over the 1.5 hr period of wakefulness. These data demonstrate across two study

populations that $R_P$ remains constant or increases during periods of waking but declines steadily

through periods of sleep.

***Association between sleep parameters and glymphatic function***

Following the overnight sleep periods, participants in the Benchmarking Study underwent CE-

MRI for the assessment of glymphatic function. Beginning at 7am, participants underwent a pre-

contrast T1-weighted MRI scan, received intravenous GBCA (Gadavist, 0.1 mmol/kg), followed

by T1-weighted MRI scans at 7-10 min ($T_{10}$) and 240 min ($T_{240}$) post-injection. We evaluated

contrast enhancement in eight regions of interest (ROIs): frontal cortical gray and white matter,

parietal cortical gray and white matter, temporal cortical gray and white matter, and occipital

gray and white matter. Contrast enhancement at the $T_{10}$ time point primarily reflects GBCA

within the blood column, while enhancement at the $T_{240}$ time point reflects GBCA leakage into

the cerebrospinal fluid (CSF) and into the brain interstitial compartments[14,15]. Glymphatic

function was defined by measuring brain parenchymal contrast enhancement, the % change in

334
**Figure 4. Brain parenchymal resistance is reduced periods of sleep. a.** Averaged EEG hypnograms
from the sleep condition are shown for the overnight period of the Benchmarking Study with WASO
excluded in both the hypnograms and sleep $R_P$ (top). Over that period, parenchymal resistance ($R_P$,
bottom) remained constant during the awake state (red) but declined gradually in the sleep state (green).
**b.** Similar trends were observed in the Replication Study. **c.** During the morning period of the
Benchmarking Study, participants underwent a 1.5 hr sleep opportunity or period of wakefulness.
Averaged EEG hypnograms for the overnight and morning periods are shown at left. At right, during the
morning awake period, $R_P$ increased gradually (dashed red), while it declined gradually during the sleep
state (dashed green). Parenchymal resistances $R_P$ shown **(a)**, **(b)** and **(c)** are the average across the
participants after normalizing each participant's $R_P$ measurements by their value at onset of the sleep or
wake period. $R_P$ in **(c)** for morning wake is plotted starting at the ending value of overnight $R_P$ for
illustration purposes. Standard error of the means are shown for each plot in light grey. The combined
overnight and morning Benchmarking Study **(c)** includes participants who's overnight and morning data
passed quality controls.
349

T1-weighted signal intensity between 10-240 min post-GBCA injection (100% * $(T_{240}-T_{10})/T_0$) within each

ROI.

To evaluate different sleep-related contributions to glymphatic function, we developed a general

random intercept mixed model with eight ROI groups fit to the $T_{10}$-$T_{240}$ change in brain

parenchymal enhancement. Our **null hypothesis** was that parenchymal contrast, including

contrast in the interstitial compartment, was not influenced by sleep variables. Glymphatic

function supports the movement of solutes into and out of the brain interstitial compartment, yet

brain parenchymal enhancement includes contrast signal from the blood compartment (the

initial source of the GBCA) and the CSF compartment (the intermediate space linking the blood

and brain interstitium) in addition to the interstitial compartment (**Figure 1f**). Thus, we defined

the **null model** to include regressors for vascular and CSF contrast in the mixed model: the $T_{10}$-

$T_{240}$ change in blood signal within the internal carotid artery, and the $T_{10}$-$T_{240}$ change in CSF

signal within the cerebral lateral ventricles. We also included the confounding biological

variables of age, gender, and APOE ε4 status in the null model *shown in* **Supplemental**

**(bottom)**. The analyses of EEG powerbands, heart rate and sleep staging were performed on

the overnight sleep period recordings. Pulse plethysmography and EEG were acquired

concurrently and heart rate, EEG powerbands, sleep stage durations (REM; N1, N2, N3

NREM), number of awakenings and wake after sleep onset (WASO) were computed and

included independently in the null model (**Supplemental Table 2**), and likelihood ratio tests

used to compare the individual predictor model with the null model. Relative EEG delta, theta,

alpha and beta powerbands were each expressed as the overnight mean of the powerband

normalized to the average powerband value of the first three sleep epochs. Higher EEG delta

power (mean 19.12, 95% CI 5.4819, 32.7599; P=0.0072), lower EEG alpha (mean -7.28, 95%

CI -12.2638, -2.2935; P=0.0052) and beta (mean -5.33, 95% CI -7.7859, -2.8728; P<0.001)

power were significantly associated with greater contrast enhancement. We next evaluated

EEG-derived sleep stages within individual mixed models. Neither number of awakenings during

the sleep period, nor wake after sleep onset (WASO) were associated with parenchymal

contrast enhancement. Lower N1 sleep time was significantly associated with greater

parenchymal contrast enhancement (mean -0.1274, 95% CI -0.2130, -0.0420; P=0.0043), while

N2, N3 and REM sleep time had no significant association with parenchymal enhancement

within these individual models (**Supplemental Table 2**). Thus, within individual mixed models,

increased overnight EEG delta band power, reduced alpha and beta band power, and reduced

time in N1 sleep are each associated with greater glymphatic function, each rejecting the null

hypothesis that parenchymal contrast was not influenced by sleep variables (**Supplemental**

**Table 2**).

*Direct association between parenchymal resistance and glymphatic function*

The device $R_P$ values were computed repeatedly throughout the overnight sleep period from

each EIS scan. During sleep recordings, the $R_P$ was non-stationary, decreasing throughout the

night as shown in **Figure 4a-c**. We observed that lower overnight $R_P$ was significantly

associated with higher glymphatic contrast enhancement (mean -38.08, 95% CI -61.34805, -

14.8115; P=0.0018, **Supplemental Table 2**).

*Combined effects of overnight parenchymal resistance, EEG spectral power, and heart*

*rate on glymphatic function*

We next utilized a comprehensive mixed model to define the contributions of $R_P$, EEG spectral

band power, and heart rate to parenchymal contrast enhancement. As in the individual mixed

models above, this comprehensive model extended the null model that contains only contrast

enhancement in the blood and cerebral ventricles as regressors, and age, APOE4 status, and

gender as confounding biological variables. We evaluated the relative delta, theta and beta

powerbands, omitting the alpha powerband to avoid multicollinearity in the model. We subjected

the model to a backward elimination algorithm with a Wald's p-value threshold of 0.05. **Table 1**

provides the full outputs of the analyses for each of the four intervention periods of overnight

sleep opportunity, morning sleep opportunity, overnight sleep deprivation and morning awake of

the study (**Figure 3**, top).

In reference to the models selected by backward elimination shown in **Table 1**, as expected,

both blood and ventricular CSF contrast enhancement were strongly associated with

parenchymal enhancement following the overnight sleep opportunity (blood mean 8.89; 95% CI

3.62, 14.16; P = 0.001; CSF mean 170.45; 95% CI 143.86, 197.04; P<0.001) and overnight

sleep deprivation (blood mean 13.09; 95% CI 7.09, 19.10; P < 0.001; CSF mean 162.36; 95%

CI 129.54, 195.19; P<0.001). For the overnight sleep opportunity, lower heart rate (mean -

54.48, 95% CI -79.51, -29.45; P<0.001) and lower $R_P$ (mean -52.55, 95% CI -74.76, -33.33;

P<0.001) predicted greater contrast enhancement. Reduced EEG beta power predicted greater

parenchymal enhancement (mean -6.29, 95% CI -8.54, -4.05; P < 0.001), while neither delta nor

theta power exhibited significant associations within the multivariate model. In the overnight

sleep deprivation condition, reduced EEG delta power (mean -20.77, 95% CI -34.34, -7.20; P =

0.004) and increased theta power (mean 7.89, 95% CI 1.13, 14.64; P = 0.026) predicted greater

parenchymal enhancement, while neither beta power, heart rate nor $R_P$ showed significant

associations within the multivariate model.

***Combined effects of morning parenchymal resistance, EEG spectral power, and heart***

***rate on glymphatic function***

As shown in the study schematic (**Figure 3**, top), between 7:10 am and 9:30am (140 min post-

injection, $T_{140}$) participants underwent MRI scanning followed by instrumentation with the

investigational device and PSG for the morning sleep opportunity or awake intervention.

Because the mean terminal half-life of intravenous GBCA in adults with normal renal function is

429
**Figure 5. Effect of sleep stages on** $R_P$**.** The mean first-order difference $\Delta R_P$ is shown by sleep
stage and study for the overnight sleep period with 95% confidence intervals. During N2, N3
and REM sleep $\Delta R_P$ is negative for each study and when combined reaches significance.
Benchmarking N2 (mean -3.21, 95% CI -9.07, -0.33; P = 0.113), N3 (mean -9.07, 95% CI -
17.04, -3.75; P = 0.005), REM (mean -8.01, 95% CI -25.64, -1.18; P = 0.133). Replication N2
(mean -12.46, 95% CI -34.94, -1.49; P = 0.115), N3 (mean -16.04, 95% CI -25.32, -5.32; P =
0.002), REM (mean -16.24, 95% CI -42.19, -4.65; P = 0.065). Combined N2 (mean -6.10, 95%
CI -14.78, -1.71; P = 0.04), N3 (mean -10.91, 95% CI -17.35, -5.93; P < 0.001), REM (mean -
10.75, 95% CI -23.86, -3.91; P = 0.023). Units of $\Delta R_P$ are mΩ.

439
440

109 min[28], the post-injection blood contrast during the morning recordings was 60% cleared by

$T_{140}$ and 80% cleared by $T_{240}$. Glymphatic function in the period between $T_{140}$ and $T_{240}$, would

therefore dilute existing parenchymal contrast with CSF having 60% to 80% lower contrast

concentration, a process analogous to 'clearance' of interstitial contrast. Thus, we would expect

that an increase in glymphatic function during the period between $T_{140}$ and $T_{240}$ would be

reflected as reduced parenchymal contrast enhancement at $T_{240}$ (**Supplemental Figure 1**).

In reference to the models selected by backward elimination in **Table 1**, once again both blood

and ventricular CSF contrast enhancement were strongly associated with parenchymal

enhancement following the morning sleep opportunity (blood mean 11.73; 95% CI 7.89, 15.57;

P < 0.001; CSF mean 145.25; 95% CI 125.08, 165.42; P<0.001) and awake intervention (blood

mean 9.83; 95% CI 5.37, 14.29; P < 0.001; CSF mean 232.52; 95% CI 210.27, 254.77;

P<0.001). During the morning sleep opportunity, $R_P$ begins to decrease (**Figure 4c**). Higher

EEG delta power (mean -35.94, 95% CI -44.10, -27.78; P < 0.001) and lower $R_P$ (mean 55.35,

95% CI 33.01, 77.70; P < 0.001) predicted reduced parenchymal enhancement (greater

contrast clearance).

During the morning awake period, $R_P$ increases from its overnight sleep ending level (**Figure**

**4c**). During this intervention, higher EEG delta power (mean -20.98, 95% CI -30.19, -11.77; P <

0.001), theta power (mean -15.27, 95% CI -19.51, -11.03; P < 0.001) and beta power (mean -

21.38, 95% CI -24.34, -18.43; P < 0.001) predicted greater contrast clearance as did lower heart

rate (mean 235.70, 95% CI 201.64, 269.76; P < 0.001) and lower $R_P$ (mean 29.38, 95% CI 5.63,

53.13; P < 0.021). These findings are similar to those observed for the morning sleep

opportunity and consistent with the explanation that an increase in glymphatic influx of CSF

during this period dilutes the ISF contrast concentration and reduces the $T_{240}$ MRI signal

intensity.

**Table 1. Multivariate models of brain parenchymal contrast enhancement using R$_p$, HR and EEG power band predictors.**

| Predictor Period | Fixed Effect Predictors | Full Model | | | Selected Model | | | Bootstrap Analysis | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Estimate | CI | p | Estimate | CI | p | Bootstrap Inclusion Frequency (%) | RMSD Ratio | Relative Conditional Bias (%) | Bootstrap Median |
| **Overnight Sleep Opportunity** | Blood CE | 10.57 | (4.89, 16.25) | **<0.001** | 8.89 | (3.62, 14.16) | **0.001** | 100 | 1.00 | -11.89 | 9.22 |
| | CSF CE | 169.37 | (141.53, 197.22) | **<0.001** | 170.45 | (143.86, 197.04) | **<0.001** | 100 | 0.96 | 0.70 | 171.06 |
| | Age | 0.50 | (-0.03, 1.04) | 0.071 | – | – | – | 29.8 | 1.40 | 63.40 | 0 |
| | Male Sex | -6.10 | (-9.89, -2.31) | **0.002** | -2.98 | (-5.63, -0.34) | **0.030** | 61.0 | 1.10 | -29.97 | -3.19 |
| | APOE ε4 | 5.13 | (1.89, 8.37) | **0.003** | 4.29 | (1.13, 7.46) | **0.010** | 71.2 | 0.84 | -1.90 | 4.08 |
| | R$_P$ | -55.47 | (-77.74, -33.20) | **<0.001** | -52.55 | (-74.76, -30.33) | **<0.001** | 70.2 | 1.03 | 2.38 | -49.70 |
| | Delta Power | 12.69 | (-1.93, 27.32) | 0.098 | – | – | – | 28.0 | 1.25 | -15.65 | 0 |
| | Theta Power | -8.69 | (-18.01, 0.63) | 0.075 | – | – | – | 18.4 | 1.77 | -9.60 | 0 |
| | Beta Power | -5.21 | (-8.11, -2.32) | **0.001** | -6.29 | (-8.54, -4.05) | **<0.001** | 98.4 | 1.03 | 14.11 | -5.96 |
| | Heart Rate | -81.28 | (-112.92, -49.63) | **<0.001** | -54.48 | (-79.51, -29.45) | **<0.001** | 93.0 | 1.63 | -26.68 | -57.59 |
| **Morning Sleep Opportunity** | Blood CE | 10.76 | 6.24, 15.29 | **<0.001** | 11.73 | (7.89, 15.57) | **<0.001** | 99.6 | 0.89 | 3.26 | 11.30 |
| | CSF CE | 154.87 | 125.96,183.78 | **<0.001** | 145.25 | (125.08, 165.42) | **<0.001** | 100.0 | 1.02 | -0.58 | 151.27 |
| | Age | -1.38 | -1.95, -0.81 | **<0.001** | -1.26 | (-1.74, -0.79) | **<0.001** | 99.6 | 1.05 | -1.70 | -1.33 |
| | Male Sex | -0.36 | -2.75, 2.02 | 0.771 | – | – | – | 13.6 | 2.38 | 425.36 | 0 |
| | APOE ε4 | -2.89 | -6.31, 0.53 | 0.109 | -3.94 | (-6.74, -1.15) | **0.007** | 53.6 | 1.17 | 58.42 | -3.17 |
| | R$_P$ | 56.58 | 32.87, 80.29 | **<0.001** | 55.35 | (33.01, 77.70) | **<0.001** | 98.6 | 1.03 | -5.03 | 53.67 |
| | Delta Power | -39.36 | -51.30, -27.42 | **<0.001** | -35.94 | (-44.10, -27.78) | **<0.001** | 100.0 | 1.03 | -2.48 | -37.30 |
| | Theta Power | 9.01 | -6.18, 24.20 | 0.259 | – | – | – | 40.0 | 1.26 | 74.24 | 0 |
| | Beta Power | -2.68 | -12.06, 6.70 | 0.585 | – | – | – | 24.0 | 1.85 | 190.46 | 0 |
| | Heart Rate | 72.92 | 44.23, 101.62 | **<0.001** | 77.55 | (49.74, 105.35) | **<0.001** | 100.0 | 0.88 | 5.61 | 77.21 |
| **Overnight Sleep Deprivation** | Blood CE | 7.42 | -0.407, 15.25 | 0.076 | 13.09 | (7.09, 19.10) | **<0.001** | 56.6 | 1.59 | 72.95 | 8.57 |
| | CSF CE | 199.82 | 152.77, 246.87 | **<0.001** | 162.36 | (129.54, 195.19) | **<0.001** | 100.0 | 1.81 | -0.67 | 193.14 |
| | Age | 0.06 | -0.60, 0.72 | 0.871 | – | – | – | 4.0 | 2.01 | -118.25 | 0. |
| | Male Sex | -6.53 | -10.37, -2.70 | **0.002** | -4.81 | (-8.05, -1.57) | **0.005** | 90.8 | 0.96 | 1.08 | -6.23 |
| | APOE ε4 | 6.17 | -0.71, 13.05 | 0.093 | – | – | – | 58.4 | 1.60 | 60.69 | 6.40 |
| | R$_P$ | 12.37 | -31.98, 56.71 | 0.600 | – | – | – | 8.8 | 1.31 | 199.07 | 0 |
| | Delta Power | -31.79 | -54.44, -9.13 | **0.009** | -20.77 | (-34.34, -7.20) | **0.004** | 85.4 | 1.24 | 12.63 | -30.78 |
| | Theta Power | 19.96 | 7.38, 32.53 | **0.003** | 7.89 | (1.13, 14.64) | **0.026** | 83.8 | 1.45 | 7.75 | 19.85 |
| | Beta Power | -17.30 | -32.72, -1.89 | **0.036** | – | – | – | 62.0 | 1.26 | 42.29 | -17.71 |
| | Heart Rate | -25.01 | -63.14, 13.11 | 0.218 | – | – | – | 44.2 | 1.75 | 97.16 | 0 |
| **Morning Awake** | Blood CE | 10.58 | 5.67, 15.49 | **<0.001** | 9.83 | (5.37, 14.29) | **<0.001** | 98.0 | 0.86 | -5.59 | 9.91 |
| | CSF CE | 232.82 | 210.603, 255.04 | **<0.001** | 232.52 | (210.27, 254.77) | **<0.001** | 100.0 | 1.07 | 0.84 | 233.00 |
| | Age | -0.88 | -1.72, -0.04 | 0.049 | -0.72 | (-1.43, -0.01) | 0.057 | 63.8 | 1.14 | 28.44 | -0.81 |
| | Male Sex | 0.96 | -1.69, 3.61 | 0.495 | – | – | – | 20.2 | 2.18 | 223.65 | 0 |
| | APOE ε4 | 11.02 | 8.30,13.74 | **<0.001** | 10.54 | (8.16, 12.92) | **<0.001** | 100.0 | 1.63 | -2.35 | 10.62 |
| | R$_P$ | 25.30 | -0.93, 51.53 | 0.071 | 29.38 | (5.63, 53.13) | **0.021** | 64.0 | 1.15 | 51.96 | 30.70 |
| | Delta Power | -22.53 | -32.67, -12.39 | **<0.001** | -20.98 | (-30.19, -11.77) | **<0.001** | 98.6 | 1.38 | -5.75 | -21.33 |
| | Theta Power | -15.37 | -19.62, -11.134 | **<0.001** | -15.27 | (-19.51, -11.03) | **<0.001** | 100.0 | 1.15 | -2.22 | -15.00 |
| | Beta Power | -21.09 | -24.15, -18.04 | **<0.001** | -21.38 | (-24.34, -18.43) | **<0.001** | 100.0 | 1.13 | 0.73 | -21.42 |
| | Heart Rate | 230.91 | 194.43, 267.38 | **<0.001** | 235.70 | (201.64, 269.76) | **<0.001** | 100.0 | 1.19 | 0.74 | 234.67 |

Parenchymal Resistance, R$_P$; Heart Rate, HR; Contrast Enhancement, CE; 95% Confidence Interval, CI; Backward Elimination, BE; Root-Mean Square Deviation, RMSD; within ROI variability, $\sigma^2$; inter-ROI variability, $\tau_{00\ ROI}$. **Bolded P values reflect significant associations at P < 0.05**. Shaded cells demark the **null model** that includes blood CE, CSF CE and potential biological confounders.

We used bootstrap analysis of the backward elimination algorithm for stability investigations on

the impact of variable selection on bias and variance of the regression coefficient and bootstrap

inclusion frequencies. We estimated the multivariate model using the backward elimination

algorithm on 500 bootstrap data replicates with replacement for each intervention period (**Table

1**). The bootstrap inclusion frequency represents the percent of the 500 backward elimination

models that retained each variable, while the bootstrap median is the median estimate for that

variable. The relative conditional bias quantified the omitted variable selection bias of each

variable from inclusion/non-inclusion of other variables from the full model. In the overnight

sleep opportunity, in addition to vascular and CSF contrast enhancement (each with an

inclusion frequency of 100%), $R_P$ (70.2%), EEG beta power (98.4%), and heart rate (93.0%) had

high bootstrap inclusion frequencies and bootstrap median estimates comparable to the

selected model estimates. Device-measured $R_P$ and ventricular contrast enhancement had the

lowest relative conditional bias, and therefore their predictions of parenchymal contrast uptake

were least affected by inclusion of the other variables. Findings in the morning sleep opportunity

also showed high inclusion frequencies of the variables retained in the backward elimination

algorithm on the full data set and bootstrap median estimates comparable to the selected model

estimates, with vascular contrast enhancement (99.6%), CSF contrast enhancement (100%), $R_P$

(98.6%), EEG delta power (100%), and heart rate (100%). These regressors also had low

relative conditional bias. These analyses suggest high model stability to perturbations of the

data set[29].

Lastly, we computed the percent of the residual variance of the null model that was explained by

including EEG power band, heart rate and $R_P$ regressors for each intervention and computed

the LRT between the null model and the intervention models. For the overnight sleep and sleep

deprivation interventions, 24.5% and 12.7% of the residual null model variance was explained

by including these regressors, respectively.  The null hypothesis that parenchymal contrast

enhancement is not influenced by these variables was rejected for the overnight sleep model

(likelihood ratio 52.6, p-value < 0.001) and the sleep deprivation model (likelihood ratio 14.1, p-

value = 0.015). Including the regressors in morning sleep and awake models explained 38.3%

and 74.8% of the residual null model variance, respectively. The null hypothesis that the

parenchymal contrast enhancement is not influenced by these variables during the morning

sleep (likelihood ratio 79.5, p-value < 0.001) and awake condition (likelihood ratio 149.6, p-value

< 0.001) were also both rejected.

***Combined effects of parenchymal resistance and sleep stages on glymphatic function***

We developed a second comprehensive mixed model to define the relationship among $R_P$,

sleep stages, heart rate and parenchymal contrast enhancement. As above, this comprehensive

model extended the null model that contained contrast enhancement in the blood and cerebral

ventricles as regressors, and age, APOE4 status, and gender as confounding biological

variables. We evaluated WASO time, and time in N1, N2, N3 and REM sleep stages.

**Supplemental Table 3** provides the model output for the overnight sleep opportunity (top) and

the morning sleep opportunity (bottom). In the overnight sleep opportunity model selected by

backward elimination, as before lower $R_P$ was significantly associated with greater parenchymal

contrast enhancement (mean -67.17; 95% CI -87.78, -46.56; P<0.001). In this model, more time

in REM sleep (mean 0.16; 95% CI 0.09, 0.23; P<0.001), and less time in N1 (mean -0.32; 95%

CI -0.43, -0.21; P<0.001), N2 (mean -0.10; 95% CI -0.15, -0.06; P<0.001), N3 (mean -0.07; 95%

CI -0.12, 0.02; P=0.007) sleep and WASO (mean -0.07; 95% CI -0.12, -0.02; P=0.006) were

each associated with greater contrast enhancement. Bootstrap analysis showed that blood and

CSF contrast enhancement (each with an inclusion frequency of 100%), as well as $R_P$ (100%),

REM sleep time (99.0%), N1 sleep time (98.8%) and N2 sleep time (98.0%)  were the most

stable elements of the model relating sleep stages to parenchymal glymphatic function, while

the RMSD ratio for N2 sleep time, N3 sleep time and WASO showed substantial variance

deflation following backward elimination (**Supplemental Table 3**) that is associated with weak

or noise predictors.

In the morning sleep opportunity model selected by backward elimination, lower $R_P$ was

significantly associated with greater parenchymal contrast clearance (mean 34.42; 95% CI 5.25,

63.59; P = 0.025), similar to the EEG band power model for this intervention. In this model, less

time in REM sleep (mean 0.41; 95% CI 0.20, 0.62; P<0.001), and more time in N1 (mean -0.26;

95% CI -0.50, -0.02; P=0.04) and N3 (mean -0.17; 95% CI -0.33, -0.021; P=0.031) were

associated with less contrast enhancement, or greater contrast clearance. N3 sleep did not

survive bootstrap analysis while $R_P$, REM and N1 sleep had inclusion frequencies of 65.4%,

88.2% and 61.6%, respectively (**Supplemental Table 3).**

***Effects of sleep stages on brain parenchymal resistance***

To understand if sleep stages had a differential effect on the overnight change in $R_P$, we

computed the mean of the first-order differences $\Delta R_P$ for each sleep stage for the Benchmarking

and Replication studies separately and combined (**Figure 5**). The mean $\Delta R_P$ was negative and

largest for N2, N3 and REM sleep stages reaching significance when the values for both studies

where pooled together.  This suggests that $R_P$ in **Figure 4a-c** decreases during N2, N3 and

REM sleep.

***Effects of large changes in EEG spectral power on brain parenchymal resistance***

To define the relationships between sleep EEG powerbands, heart rate and $R_P$, we modeled the

relationship between the first-order difference $\Delta R_P$ and the difference in spectral band power

($\Delta$delta, $\Delta$theta, $\Delta$alpha, $\Delta$beta) and changes in heart rate $\Delta HR$, during NREM, REM and Wake

(**Table 2**). We utilized threshold regression to model the relationships between $\Delta R_P$ and large

555 **Table 2. The change in parenchymal resistance resulting from large changes in EEG**
556 **band power and heart rate occurring during REM sleep, NREM sleep, wake, and at NREM-**
557 **REM and sleep-wake transitions.**
558

| Study Condition | Period | Predictors | Fixed Effects | | | | Threshold Model Parameters | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | Estimate | CI | p | DF | Positive Threshold | Negative Threshold | Slope Ratio |
| Overnight Sleep Op | NREM | Δdelta | -0.28 | (-0.50, -0.058) | **0.014** | 1380 | 1.5 | -1.5 | 0.7 |
| | | Δtheta | -0.08 | (-0.23, 0.063) | 0.265 | 1380 | 1.5 | -0.98 | 0.5 |
| | | Δalpha | -0.14 | (-0.30, 0.022) | 0.091 | 1380 | 1.5 | -1.25 | 0.65 |
| | | Δbeta | 0.04 | (0.0022, 0.080) | **0.039** | 1380 | 0.18 | -1.5 | 2 |
| | | ΔHR | 0.10 | (-0.0033, 0.19) | 0.059 | 1115 | 0.43 | -0.43 | 0.5 |
| | REM | Δdelta | -0.57 | (-0.77, -0.37) | **<0.001** | 319 | 1.5 | -1.5 | 2 |
| | | Δtheta | -0.41 | (-0.70, -0.13) | **0.005** | 319 | 0 | -1.5 | 0.5 |
| | | Δalpha | -0.09 | (-0.21, 0.041) | 0.189 | 319 | 1.45 | 0 | 2 |
| | | Δbeta | 0.45 | (0.14, 0.77) | **0.006** | 319 | 1.5 | -1.3 | 0.5 |
| | | ΔHR | 0.31 | (-0.057, 0.68) | 0.101 | 271 | 1.5 | -1.15 | 0.5 |
| | NREM to REM | Δdelta | -0.29 | (-0.82, 0.24) | 0.293 | 67 | 1.5 | -1.05 | 2 |
| | | Δbeta | 0.77 | (0.04, 1.49) | **0.046** | 67 | 0.6 | -1.5 | 0.5 |
| | REM to NREM | Δdelta | -1.50 | (-2.35, -0.66) | **0.001** | 58 | 1 | -1.5 | 0.5 |
| | | Δbeta | -0.05 | (-0.24, 0.14) | 0.615 | 58 | 0.1 | -1.5 | 1.85 |
| | Sleep to Wake | Δdelta | 0.03 | (-0.34, 0.4) | 0.885 | 66 | 1.5 | -0.3 | 1.95 |
| | | Δbeta | 0.73 | (0.13, 1.32) | **0.021** | 66 | 0.35 | -1.23 | 0.5 |
| | Wake to Sleep | Δdelta | -0.20 | (-0.64, 0.25) | 0.392 | 113 | 0.05 | -1.35 | 0.6 |
| | | Δbeta | 0.37 | (-0.01, 0.76) | 0.065 | 113 | 1.5 | -1.05 | 2 |
| Overnight Sleep Deprivation | WAKE | Δdelta | -0.06 | (-0.15, 0.034) | 0.216 | 1137 | 1.5 | 0 | 0.5 |
| | | Δtheta | -0.07 | (-0.17, 0.035) | 0.198 | 1137 | 1.4 | -1.45 | 2 |
| | | Δalpha | 0.06 | (-0.030, 0.14) | 0.206 | 1137 | 1.15 | 0 | 0.73 |
| | | Δbeta | 0.12 | (0.0075, 0.23) | **0.037** | 1137 | 1.5 | -1.43 | 1.93 |
| | | ΔHR | -0.10 | (-0.20, -0.011) | **0.029** | 1002 | 0.25 | -0.25 | 0.5 |

Rapid eye movement, REM; non-REM, NREM; Confidence Interval, CI; Degrees of Freedom,
DF; EEG band power predictor units in percent of total band power; HR predictor units beats-
per-minute. **Bolded P values reflect significant associations at P < 0.05**. Predictor and
parenchymal resistance values in regression models were scaled to zero mean and unit
standard deviation with coefficient estimates representing effect size in standard deviations.
Positive and negative thresholds are in units of predictor standard deviation. Models included
confounding biological variables age, gender, and APOE ε4 status.
566

associated with an increase in $\Delta R_P$. The threshold models for the significant estimated effects of

$\Delta$ band power on $\Delta R_P$ are plotted in **Figure 6b**. The full output of the threshold regression model

is provided for each site individually in **Supplemental Table 4**. Because the variables were

standardized before model estimation, the regression estimates in **Table 2** and **Supplemental**

**Table 4** can be interpreted as standardized effect sizes. Note that because of the slope ratio $r$,

changes that exceed the positive change point $t_p$ have effect sizes given by the regression

estimate multiplied by the slope ratio. The positive and negative thresholds are in units of

standard deviation.

The asymmetric effect of EEG band power changes on $R_P$ shown in Figure 5 accounts for the

progressive decline in $R_P$ that occurs through the course of the overnight sleep period, shown in

**Figure 4a-c**. In the overnight wake state, $\Delta$beta had a significant but small effect on $\Delta R_P$. $\Delta HR$

in NREM and wake had a small effect on $\Delta R_P$ and a larger but non-significant effect in REM.

The threshold model findings in **Table 2** and plots in **Figure 6a** demonstrate that large changes

in spectral band power are needed to alter $R_P$. Because such large changes in EEG

powerbands and HR occur at sleep stage transitions, we explored the associations between

$\Delta$delta and $\Delta$beta and $\Delta R_P$ at NREM-REM and REM-NREM transitions, and at Sleep-Wake and

Wake-Sleep transitions. **Table 2** provides the full model output on sleep stage transitions for

data pooled from both study sites, while the significant estimated effects of $\Delta$delta and $\Delta$beta on

$\Delta R_P$ are plotted in **Figure 6c**. The full output of the threshold regression model on sleep stage

transitions is provided for each site individually in **Supplemental Table 5**. During the NREM-

REM, Wake-Sleep, and Sleep-Wake transitions, changes in EEG beta power and not EEG delta

power underlie the observed changes in $\Delta R_P$. In contrast, during the REM-NREM transition,

changes in EEG delta power and not beta power were associated with changes in $\Delta R_P$. In total,

**a**

### Relationship Between Large Changes in EEG Spectral Power
### and Changes in Parenchymal Resistance

**b**

**c**

592
**Figure 6. Brain parenchymal resistance is increased by large changes in EEG beta power**
**and reduced by large changes in EEG delta power. a,** Threshold linear mixed regression
model of $R_P$ against EEG delta and beta power for REM and NREM sleep shown with standard
error after differencing both $R_P$ and powerband values to make data stationary, standardizing
the $\Delta R_P$ and $\Delta$ powerband values to zero mean and unit standard deviation, and adjusting for
site, age, gender, APOe4 and site-age interaction confounders. Units of $\Delta R_P$ and $\Delta$ powerband
are in standard deviations. Data in light blue are inside the change points and data in dark blue
are outside the change points. When delta and beta power changes between successive
measurements exceed 1.0 to 1.5 stand deviations, we observe significant changes in $\Delta R_P$. **b,**
95% CI of regression coefficients show that large changes in REM delta, theta and beta, and
NREM delta and beta are significant predictors of $\Delta R_P$. For a 1 standard deviation increase in $\Delta$
powerband, an increase (decrease) in $\Delta R_P$ is illustrated in red (green) with units along the top in
standard deviation of $\Delta R_P$. **c,** Large changes in beta and delta powerbands at sleep-wake and
NREM-REM transitions show significant effect on $\Delta R_P$ consistent with the step change in beta
and delta power at these transitions. For a 1 standard deviation increase in $\Delta$ powerband across
a sleep-wake or NREM-REM transition, an increase (decrease) in $\Delta R_P$ is illustrated in red
(green) with units along the top in standard deviation of $\Delta R_P$.

these data show that glymphatic function is enhanced by declining $R_P$, and that $R_P$ in turn

declines with reduced EEG beta power and heart rate, and with increasing EEG delta power.

**DISCUSSION**

We have described a non-invasive multimodal skin-interfaced wireless device for continuous

measurement of brain parenchymal resistance $R_P$ using repeated EIS time-multiplexed with

EEG and cardiovascular measurements. Through two separate clinical validation studies, we

observe that brain $R_P$ measured by the device faithfully captures sleep-active changes in

glymphatic flow resistance based on three complementary criteria established from studies in

the murine and human brain. Brain $R_P$ declines overnight, paralleling sleep-associated changes

in extracellular volume that regulate glymphatic function[2]. Brain $R_P$ is reduced with increasing

sleep EEG delta power, and is increased with increasing sleep EEG beta power and heart

rate[11]. Lastly, brain $R_P$ is a robust predictor of glymphatic function, measured by CE-MRI[12-15,30].

These findings demonstrate that this investigational device provides the first remote, non-

invasive, and time-resolved measure of glymphatic flow resistance suitable for defining this

sleep-active biology in naturalistic settings.

Several technological advances have enabled this work. We have developed a technique for

low-noise EIS measurements using multiple excitation and sense configurations to determine

the brain parenchymal impedances accurately. A signal processing approach enabled the

segregation of signal and noise, using the Kramers-Kronig relations[31,32] between the real and

imaginary parts of the impedance to establish if the measured response is related to the

excitation signal or has been distorted by noise or other artifact. Unlike applications of EIS to

neurological conditions such as seizures, tumors or cerebral edema[33-36], the rapid evolution of

glymphatic function during sleep and its nightly variability make it suitable for monitoring with

longitudinal repeated assessments. Data collected under a variety of scenarios in benchtop

testing, agar phantom testing with biological interfaces and in-human testing indicate that this

system yields consistent, repeatable results and shows longitudinal stability of the measured

impedances.

A key first step in validating any potential measure of glymphatic function is assessing its

performance against established, principally contrast-based, measures of glymphatic exchange.

Initial studies characterizing glymphatic function in rodents utilized dynamic in vivo

fluorescence-based imaging[1,2,37].  More recent studies in rodents, and recently in human

participants, have utilized CE-MRI following either intrathecal or intravenous GBCA

injection[12,14,15,30,38]. We evaluated whether device-based $R_P$ measures reflect glymphatic

function by measuring overnight and morning $R_P$, EEG, and the movement of GBCA into brain

tissue over a four-hour timeframe. In the analysis, both overnight and morning $R_P$ emerged as

robust explanatory variables of net contrast movement, in a regression model that included CSF

and blood contrast levels, EEG neurophysiological parameters, age, gender and APOE e4

confounders. It is important to note that device-based $R_P$ measures are acquired with 2-minute

temporal resolution whereas CE-MRI captures overall glymphatic function over a 4-hour

window. This fine temporal resolution enabled translational validation of the physiological drivers

of glymphatic function in the human brain for the first time. It further revealed that while key

events during sleep were necessary to lower parenchymal resistance $R_P$, low $R_P$ was sufficient

to enhance glymphatic function independent of sleep in the morning period. In addition, it

showed that sleep-related changes in RP do not shift with sleep-wake in a stepwise fashion, but

rather accumulate through the course of time spent sleeping or awake. These observations are

not inconsistent with prior studies in rodents that used real-time iontophoresis to measure sleep-

associated increases in brain extracellular volume fraction[2], as these observational studies did

not directly test the causal effect of these changes in extracellular volume on glymphatic

function, and did not monitor changes in extracellular volume fraction in a time-resolved manner

over extended period. Future studies of the determinants of glymphatic function in human sleep

will likely further refine existing conceptual models of sleep-wake regulation of glymphatic

function.

The physiological mechanisms regulating glymphatic function have been defined almost

exclusively through experimental rodent studies[1,2,10,11,30,37,39,40], due in large part to invasiveness

and poor temporal resolution of contrast-based measures of glymphatic function[12-15,30]. It is

noteworthy that these rodent studies are not all in agreement. While multiple studies have

reported more rapid glymphatic exchange under conditions of sleep, or under certain anesthetic

regimes[2,11,41-45], two studies[46,47] have reported apparently slower clearance during sleep or

under anesthesia. In the present human clinical studies, we demonstrate within-participant

longitudinal declines in brain $R_P$ during overnight sleep, but not in awake participants. During

morning recovery sleep, we demonstrate within-participant longitudinal declines in brain $R_P$ and

during morning wake we observe increases in brain $R_P$. This pattern is consistent with sleep-

wake changes in extracellular volume fraction measured in mice and reported by Xie et al.[2].

Using overnight PSG followed by CE-MRI in human participants, we confirmed that glymphatic

function in the human brain is associated with lower EEG beta power and heart rate, and in a

simplified model with increasing EEG delta power. These findings sustain the physiological

findings in mice from Hablitz et al.[11]. More broadly, these human CE-MRI-based imaging studies

demonstrate that glymphatic solute exchange is more rapid under conditions of natural sleep, at

least in human participants, and that these sleep-wake differences are regulated by sleep-

related changes in $R_P$, heart rate, and EEG spectral band power.

Linking changes in $R_P$ with sleep EEG features, we further demonstrate that the investigational

device-based measure of $R_P$ exhibits the same dependence upon EEG delta power, EEG beta

power, and heart rate during sleep. Conducting parallel time-resolved sleep EEG and $R_P$

measurements, we observed that rapid changes in $R_P$ occurred at sleep stage transitions

between REM and NREM, and between sleep and wake. Transitions between REM and NREM

exhibit large changes in EEG delta and beta powerbands, and in HR, consistent with our

findings. Large changes in an EEG power within a frequency band can occur because of

sudden bursts of oscillatory activity within the band's frequency range. In rodents, recent

experiments support a role for such synchronized oscillatory activity as a mechanism driving

glymphatic flow by creating propagating ionic waves within the brain interstitium[41]. To our

knowledge, this is the first time that these physiological drivers of glymphatic function have been

confirmed in human participants, within an experimental setting permitting validation against

current benchmark CE-MRI-based measures of glymphatic function well established preclinical

features.

There are clear limitations both of the investigational device, and of the present study design.

Existing MRI-based measures of glymphatic function remain poorly time-resolved but provide

excellent cranium-wide anatomical resolution. In contrast, the present investigational device

captures a measure of global brain glymphatic flow resistance with high temporal resolution.

While finer anatomical resolution may have value in future iterations of the investigational

device, it is important to note that the present design was sufficient to capture sleep-wake

changes in glymphatic function, and to define novel neurophysiological drivers of these

processes in the human brain. Study methodological limitations include protocol differences

between the Benchmarking Study and Replication Study. The Benchmarking Study included

CE-MRI as part of the neuroimaging package and gold-standard PSG concurrent with the

device usage whereas the Replication Study did not include CE-MRI and used the device's

single-derivative EEG. Furthermore, the Benchmarking Study enrolled participants 55-65 years

old living in Florida whereas the Replication Study enrolled participants 50-65 years old living on

the West Coast. Despite these differences, after adjusting for age, study site and age-site

interaction effects, we confirmed that the device's single-derivative EEG showed good

agreement with the PSG of the Benchmarking Study. Additionally, the pooled analysis and

study-specific analyses of $R_P$, EEG and HR were all in good agreement between studies. The

Benchmarking Study was powered to detect a low to moderate correlation between $R_P$ and CE-

MRI measures of glymphatic function, which was confirmed. Quality control of the

investigational device filtered out measurements that did not satisfy the Kramers-Kronig

relations[31,32]. Failed measurements were more common in the Benchmarking Study, particularly

during the awake conditions. This is attributable to excessive motion, likely due to the technical

challenges associated with conducting concurrent PSG and device-based sleep EEG measures

in participants being kept awake by study staff. The low rate of quality-control failures in the

Replication Study that did not involve PSG instrumentation supports this conclusion.

The characterization of the glymphatic system in rodents beginning in 2012 has spurred a great

deal of interest into its potential mechanistic role linking sleep to cognitive performance, and

sleep disruption to a wide range of neurological and psychiatric conditions including Alzheimer's

disease, Parkinson's disease, chronic traumatic encephalopathy, stroke, traumatic brain injury,

headache and others[42-45]. Preclinical studies have demonstrated that glymphatic function is

impaired in the setting of aging[48], sleep disruption[2], cerebrovascular injury[49,50], and traumatic

brain injury[3], all risk factors for neurodegenerative conditions including Alzheimer's disease.

Experimental impairment of glymphatic function is sufficient to promote the development of the

amyloid beta[51-53] and tau pathology[3-5] characteristic of Alzheimer's disease. In clinical

populations, genetic and histological associations support a link between glymphatic dysfunction

and the development of clinical disease[52,54-56]. Yet the technical challenges of real-time dynamic

measurements of glymphatic function in human clinical populations have proven a challenging

barrier to defining the causal role of glymphatic function and dysfunction in the development of

neurological and psychiatric conditions in these populations. Whether glymphatic dysfunction

contributes to development of conditions such as Alzheimer's disease remains to be directly

tested. The present investigational device may permit the continuous and time-resolved

assessment of glymphatic function in naturalistic settings necessary to define whether

glymphatic impairment contributes to risk and progression of Alzheimer's disease and its

underlying pathological processes. The ability to assess glymphatic function over short

timescales may enable target-engagement studies to identify and test pharmacological, device-

based and lifestyle/behavioral interventions for modulating glymphatic function in humans.

Assessment of these processes may also permit the identification of clinical populations with

impaired glymphatic function, at risk for the development of Alzheimer's disease, and who would

thus be ideal candidates for therapeutic approaches targeting glymphatic clearance. Similar

avenues now remain open outside the realm of neurodegenerative conditions as glymphatic

dysfunction is implicated in an ever-increasing list of sleep-related neurological and psychiatric

conditions.

**METHODS**

***Investigational Device***

*System Architecture*

The Applied Cognition device is a wearable multi-sensor acquisition system that uses an

STM32WB5MMG microcontroller (ST Microelectronics, NV). It consists of a primary module

housing the main electronics board and a 430 mAh Li-ion battery, two earpieces each housing

one electrode, one accelerometer and one photoplethysmogram sensor, and two separate

mastoid electrodes. A device schematic and visualization of signal outputs is provided in

**Figure 2a-f**. Sensor data is stored in on-board FLASH memory and is downloaded via a USB

port for offline analysis. The relevant sub-systems are further described below.

*Electrical Impedance Spectroscopy*

Electrical impedance spectroscopy (EIS) was used to measure electrical impedance using the

AFE4500 analog front-end (AFE) from Texas Instruments. Four electrodes – two in-ear and two

mastoid – were used to deliver the excitation current across the head and sense the resulting

voltage. The two mastoid current injection sources were initially co-located inside the ear next to

the Ag/AgCl sensors but because of salt-bridging were externalized to the mastoids. In a

departure from traditional four-electrode measurements, where excitation and sense electrodes

are fixed, the AFE4500 was programmed to implement a technique developed by Texas

Instruments where multiple excitation and sense configurations are used to determine the

contact impedance and body impedance accurately.

Measurements were successively performed at eighteen frequencies ranging from 1 kHz to

256 kHz following a logarithmic series, all with excitation current below 50 $\mu$A root-mean-square

(rms). Frequencies were in alternating order from high-low to minimize any impact on

impedance drift during each scan. Sensed voltages were quadrature-demodulated, filtered and

digitized internally by the AFE4500 to provide in-phase and out-of-phase components.

Measurement time for each frequency was adjusted to give consistent signal-to-noise ratio

across the frequency range, resulting in a scan time of 106 seconds.

*Electroencephalogram*

Electroencephalogram (EEG) was measured with an ADS1299-4 AFE from Texas Instruments,

between the two in-ear electrodes (differential measurement). A third electrode (left mastoid)

was used to drive the common mode. While these electrodes were shared with the EIS, the two

measurements were time-multiplexed and a pair of analog multiplexers (TMUX1136, Texas

Instruments, Inc.) effectively decoupled EEG and EIS sub-circuits and respective

measurements. For EEG, both in-ear electrodes were also buffered (OPA376, Texas

Instruments, Inc.) in the earpiece. These buffers were bypassed (analog multiplexer

TMUX1136, Texas Instruments, Inc.) for EIS or electrode impedance measurement.

The ADS1299-4 was programmed to have a sampling rate of 250 samples-per-second (24-bit

samples) and an input range of ±180 mV. The common mode drive was actively derived from

the in-ear electrodes. Both mastoid electrodes were also connected to an input channel so that

the low-frequency (31.25 Hz) impedance of each electrode could be measured using the

internal current source of the ADS1299-4. Such impedance measurements were performed

before starting a recording session, and then automatically between EEG periods and EIS. EEG

measurement periods were 170 seconds long, and the sequence EEG-EIS-Electrode

impedance repeated until the end of the recording session. A sample EEG spectrogram and

hypnogram, derived from the device EEG is shown in **Figure 2b**.

*Impedance Plethysmogram*

In addition to impedance spectroscopy, real-time bioimpedance was acquired simultaneously

with the EEG, using the MAX30001 AFE (Analog Devices, Inc.). The four-electrode

configuration shared electrodes with the EEG, with the two mastoid electrodes used for current

injection and the two in-ear electrodes for voltage sensing. A 96 $\mu$A current at 82 kHz was used

for excitation. Such high frequency excitation is effectively filtered by the ADS1299-4 and does

not corrupt the EEG signal. The MAX30001 built-in synchronous demodulator filtered and ADC

recovered the in-phase component of the sensed voltage and digitized it at 64 samples-per-

second (20-bit resolution). The resulting impedance measurements had a noise floor of 3 m$\Omega$

rms (100 $\Omega$ load), enabling the detection of blood pulsations. A sample trace from a study

participant, derived from the device IPG is shown in **Figure 2d.** Note that the impedance shifts

measured in either the respiratory or cardiac frequency bands range between 50 to 150 m$\Omega$. In

contrast, impedance shifts detected by EIS were at least an order of magnitude greater.

*Photoplethysmogram and Acceleration*

In-ear reflective photoplethysmogram (PPG) was measured with two miniature, fully-integrated

optical sensors MAXM86161 (Analog Devices, Inc.) located in each earpiece, facing the anterior

wall of the ear canal. One side was programmed to use green light (530 nm), while the other

used alternatively red (660 nm) and infrared (880 nm) lights. To achieve a tight synchronization

with EEG samples, the sensors ran at 1024 Hz for each color, and the most recent samples

available at the time of the EEG read were averaged, resulting in a 250 Hz output rate and a

phase variation <1 ms. A sample trace of the left (red) and right PPG (green) from a study

participant is provided in **Figure 2f.**

In-ear acceleration (X,Y,Z) was measured using two miniature MEMS Inertial Measurement Unit

(IMU) LSM6DSOX (ST Microelectronics, NV) located in each earpiece. Similar to the PPG, the

sensors were run at 833 Hz (each axis) and averaged to ensure tight time synchronization

between sensors. A noise floor of 1 mg rms enabled the resolution of cardiac/blood pulsations,

in addition to posture and activity. From these accelerometer data, a ballistocardiogram is

derived, as shown for a study participant in **Figure 2e**.

*Electrodes*

In-ear electrodes were laser-cut from silver sheets 100 microns thick and 99.9% purity. The

electrodes were 4.5 mm diameter plates with a 1 mm-wide stem. The electrodes were abraded

and sonicated in distilled water, dip-coated with Ag/AgCl ink provided by Creative Materials Inc

(SKU EXP 2653-138-1) and cured at 100°C for 60 min. Following curing, they were sintered at

427°C for 60 minutes under low-flow argon gas.

Once fabricated, all electrodes were characterized according to the ANSI/AAMI EC12 standard

for AC impedance[57], DC offset voltage, combined offset instability and internal noise, and bias

current tolerance (**Supplemental Table 7**). Pairs of electrodes were also connected to the

earpiece circuits with clip-on wires and tested on an agar phantom as described in the *Device*

*Testing* section.

*Electrical Impedance Spectroscopy Validation*

Measurement accuracy was first evaluated using a test fixture simulating the load and the four

electrodes (**Supplemental Figure 2**). The load was either purely resistive ($R$, 20-100 $\Omega$), or

slightly reactive (*2R1C*, 20-100 $\Omega$ in parallel with 470 $\Omega$ and 22 nF in series) to mimic the brain

parenchyma. The electrodes were implemented as either (i) low impedance (270 $\Omega$ resistor in

series with a 1 k$\Omega$ resistor and 180 nF capacitor in parallel), or (ii) high impedance (620 $\Omega$

resistor in series with a 3.3 k$\Omega$ resistor and 82 nF capacitor in parallel), in order to simulate the

frequency-dependence of typical Ag/AgCl electrodes, but also to ensure a minimal impedance

at high frequencies. Two 10 Ω resistors were added between the electrodes connected to the

same side of the load to simulate the tissue impedance between these electrodes as well.

**Supplemental Table 8** describes the benchtop tests performed and **Supplemental Table 9**

and **Supplemental Table 10** contain the results.

*Device Testing*

In addition to the EIS test fixture, stability and reproducibility of EIS measurements over twelve

hours were evaluated with an agar phantom. A slab (5-10 mm thick) of conductive agar was first

cast using a solution of 2.5% weight agar (Living Jin USA, Inc.), 0.64% weight NaCl (RND

Center, Inc.) and distilled water. Electrodes (mastoids and earpieces for the final testing) were

then coated with conductive gel (Electro-Gel, Electro-Cap International) to reduce the contact

resistance, and placed on the agar slab in a pattern geometrically similar to the electrode

location on the head. A 12-hour recording was performed, resulting in a total of 450 minutes of

EEG recording, 159 EIS cycles and 160 electrode impedance checks. The results of a 12 hr

agar phantom EEG test is shown in **Supplemental Figure 3.**

*Signal Processing – Parenchymal Resistance*

A python neuroprocessing pipeline developed by Applied Cognition performed the data analysis

of the signals captured by the investigational device. The neuroprocessing pipeline runs in the

Amazon Web Services cloud on a distributed architecture allowing for fast parallel execution of

participant device readings.

An EIS scan by the investigational device measured impedances Z(ω) at 18 frequencies $f$ ($\omega =$

$2\pi f$) ranging from 1,000 Hz to 256,000 Hz and took 106 seconds. The frequencies were

measured in the following permuted order for each scan (all in Hz): 2276, 102400, 1600, 64000,

4551, 51200, 12800, 85333, 3200, 25600, 1000, 32000, 6400, 8533, 128000, 204800, 256000.

During the EIS scan, all other device sensors were powered off except the left-in-ear IMU that

sampled at 1Hz to detect head motion and position. The EIS scans were duty-cycled throughout

the recording period with 165 second neurophysiology scans that captured data from the other

sensors: EEG, PPGs and IMUs. Four electrode impedance checks at 30Hz and lasting 7

seconds were performed during the neurophysiology scan and immediately preceding the EIS

scan.

The Cole-Cole model[58-60] is commonly used to analyze EIS data. The analysis is based on the

four parameters contained in the Cole equation $R_0$, $R_\infty$, $\alpha$ and $\tau$.

892
$$Z(\omega) = R_\infty + \frac{R_0 - R_\infty}{1 + (j\omega\tau)^\alpha}$$

As the excitation frequency ω ($\omega = 2\pi f$) increases to large values, the capacitive cell

membranes are invisible to the excitation frequency and the impedance Z(ω) approaches $R_\infty$.

The four excitation and response electrodes are positioned trans-cranially and at large ω

measure total intracranial brain volume. As the excitation frequency ω decreases approaching

DC values, the capacitive cell membranes prevent any transmembrane conduction and the

impedance Z(ω) approaches $R_0$ the measure of electrical resistance through extracellular fluid.

The value of τ in the Cole-Cole model is the inverse of tissue characteristic frequency $2\pi f_c$. The

Cole-Cole α describes the divergence of a measured dielectric dispersion from the ideal

dispersion exhibited by a Debye type of dielectric relaxation, and is widely assumed to be

related to a distribution of the relaxation times in the system involved. The value of α ranges

from 0.5 to 1 with a value of 1 reducing the Cole-Cole model to the Debye model.

For each EIS scan, the four parameters were estimated using a non-linear least-squares fit

(Python SciPy's least_squares) with the Trust Region Reflective algorithm that is a robust

method suitable for large sparse problems with bounds. The α parameter was found to be close

to one in the estimations and thereafter set to one, reducing the Cole-Cole model to the Debye

model. The remaining three parameters were estimated with bounds of 0 to 90Ω for $R_0$, 0 to 70Ω

for $R_\infty$ and bounds for $\tau = \frac{1}{2\pi f_c}$ determined by requiring the characteristic frequency $f_c$ to lie

between 16kHz and 160kHz. The parameter bounds where confirmed to encompass

neurophysiological values in all participants by plotting all EIS scan resistance (real values of

impedances Z(ω)) and reactance (imaginary values of impedance Z(ω)). Furthermore, no

parameter solutions lay on a boundary for each scan across the range of dynamic impedance

spectroscopy measurements for all participants.

Prior to fitting the Debye model to the EIS scan data, to compensate for stray capacitance, time

delay effects from signal transmission and electrical components, the impedances Z from each

scan were rotated by multiplying by the factor $e^{-j\omega T}$ with the value $T$ chosen so that the

reactance at the highest frequency of the scan was zero[59]. This rotation was independently

validated using EIS scans recorded on the benchtop tests using known impedance loads

(**Supplemental Table 10**). The root-mean-squared-error (RMSE) of the Debye model fits to the

benchtop tests (**Supplemental Table 8)** are reported in **Supplemental Table 11**.

Each EIS scan measures $R_P$ at a point in time and to evaluate glymphatic function the Debye

model fits need to detect small changes in $R_P$. With the device time-multiplexing settings, the

device completes approximately 84 scans over a 7-hour night of sleep. The statistical models

require significance testing of the mean change in $R_P$ between sleep and wake, and testing

significance of predictors of $R_P$ in linear mixed models. These tests depend on the SD of the

Debye model dispersion and the number of EIS scans (**Supplemental Table 12**). Details of

these analyses are found in **Supplemental 4**.

During EIS, tissue behaves as a linear, time-invariant and causal system allowing the use of

Kramers-Kronig relations to identify electrical impedance measures that are corrupted by

artifacts from motion, electrode impedances and other sources[31,32]. The Kramers-Kronig

transform allows the real part of the electrical impedance measure to be derived from the

imaginary part and vice versa[31]. These relations are used as validity tests for measured

spectrums. When the real and imaginary impedance measures do not satisfy the Kramers-

Kronig relation the measure is discarded. The Python PyEIS1.0.10 repository was used for

Kramers-Kronig impedance validation. The validation uses the method of Schönleber[32] to avoid

ambiguities in the linear Kramers-Kronig validity tests due to under- and over-fitting.

In addition to the Kramers-Kronig validity tests, EIS measures were discarded if for any of the

four electrode impedances, the difference across successive time measures exceeded 1kΩ or if

the EIS scan was collected during a wake interval on a participant randomized to sleep. The first

condition ensured that the electrode impedances were maintained within a narrow range during

the EIS scans and the second condition ensured that the EIS scans were representative of

sleep physiology for participants randomized to sleep.

*Signal Processing – Electroencephalography*

The raw EEG tracings from the device and the commercial PSG (Philips Respironics Alice 6

LDx Diagnostic Sleep System) were time-synchronized by time-aligning a 100-ms square pulse

generated by the device every 10 seconds and stored both in the device flash memory and in

the PSG recording through as an unused auxiliary analog input channel. Each raw tracing was

notch filtered at 60 Hz using a second-order infinite impulse response (IIR) notch digital filter

(Python SciPy *iirnotch*). The digital filter was applied to the signal forward and backward with a

combined filter phase of zero (Python SciPy *filtfilt*). The signal was then bandpass filtered

between 0.3 Hz and 50 Hz using a finite impulse response (FIR) filter with a Hann window

(Python SciPy *firwin*). The length of the low-pass filter was 501 and the length of the high-pass

filter was 2,401.

During the observation periods, participants were not allowed to touch devices that were

plugged to power outlets. Other non-physiologic sources included excessive head motion that

led to signal artifacts from the electrode-skin interface. Physiologic sources of signal artifact

included electrooculogram, electrocardiogram and electromyogram. The signals where

partitioned into time-aligned 30- second epochs. Epochs containing one or more peak-to-peak

signal amplitude exceeding 350 µV or maximum power in the Welch power spectrum exceeding

1,000 $µV^2$/Hz were removed. In addition, the device left in-ear and right-in ear IMU signals were

used to filter excessive motion by filtering epochs with peak-to-peak values on an x-, y-, or z-

axis on either ear that exceeded 100 milli-g during sleep and 200 milli-g during wake.

The power spectral density of each 30-second epoch was computed using Welch's method[61]

(Python Scipy *welch*) using 10-second segments and 50% overlap across successive

segments. Relative power bands were computed for delta power (1-4 Hz), theta power (4-8 Hz),

alpha power (8-12 Hz), sigma power (12-15 Hz), beta power (15-30 Hz) and low gamma power

(30-50 Hz), each normalized to the total power in the power spectral density. Simpson

integration of the power spectral density was used for computing the total power and respective

band powers.

Hypnogram staging of each 30-second epoch used automated scoring (Python yasa 0.6.3

*SleepStaging*) trained and validated on 3,000 nights of data from the National Sleep Research

Resource[62]. The automated scoring uses a single EEG derivative and a single EOG channel.

For device hypnogram staging the single in-ear transcranial derivative was used and for the

commercial PSG, hypnogram staging using C3-A2 and C4-A1 derivatives were recorded

separately. The PSG left EOG channel was used for commercial PSG hypnogram staging. An

additional T3-T4 transcranial PSG derivative was used for hypnogram staging as another

comparison to the device's transcranial in-ear derivative. The internal agreement of commercial

PSG and agreement between investigational device-based EEG and PSG are presented in

**Supplemental Table 6**.

*Signal Processing – Heart Rate*

The photoplethysmography (PPG) left and right raw signals were bandpass filtered between 0.5

Hz and 10 Hz using a finite impulse response (FIR) filter with a Hann window (Python SciPy

*firwin*). Empirical mode decomposition was used to identify peaks in the raw signals (Python

emd 0.6.2) using a box-car rolling window of 100 observations[63]. Heart rate variability metrics

were computed after removing outliers, ectopic beats and interpolating missing values (Python

Aura-healthcare *hrvanalysis*). Both time-domain features (standard deviation (SD) of the inter-

beat-interval of normal sinus beats, *sdnn*) and frequency-domain features using the Lomb-

Scargle periodogram [ref] (low-frequency signal power *lf* between 0.04-0.15 Hz considered a

mixture of sympathetic and parasympathetic activity, high-frequency signal power *hf* between

0.15-0.4 Hz representing beat-to-beat changes from parasympathetic vagal activity, and the

low-frequency to high-frequency ratio (*lf-hf-ratio*) were computed[64].

The device inertial-measurement units (IMU) were located inside the left and right ear canal and

provided left and right cartesian coordinates of acceleration measured in milli-g where 1,000

milli-g is the acceleration caused by earth's gravitational force. Each in-ear component from the

device is uniquely and reproducibly oriented on account of the ellipsoidal shape of the human

ear-canal and the matching shape of the in-ear component. From this orientation, head position

and motion (acceleration) were resolved from each set of IMU samples that included gross

positions such as *supine*, *reclined*, *upright*, *left* and *right*.

1011

***Clinical Study Design***

The Investigational Device was evaluated in two studies, a Benchmarking Study conducted in

The Villages community in Florida in partnership with the UF Health PHRC, and a Replication

Study conducted at the University of Washington in Seattle. These studies were reviewed and

approved by University of Florida Institutional Review Board (IRB No. 202201364) and Western

Institutional Review Board (IRB No. 20225818), respectively. Written informed consent was

obtained from all study participants during a screening visit, prior to any study activities.

1019

*Participant Recruitment*

Following distribution of study flyers in public-facing locations in senior recreation and/or local

medical centers, the Benchmarking Study enrolled 34 healthy participants 56-66 years of age

and the Replication Study enrolled 14 healthy participants 49-63 years of age. Participants were

cognitively intact and had no history of clinical depression, confirmed during screening using the

Montreal Cognitive Assessment (MOCA) and Geriatric Depression Scale (GDS). Other

exclusion criteria included a history of diabetes, hypertension, coronary artery disease,

pulmonary disease, neurological disease, or anxiety. Participants planning travel to alternate

time zones within two weeks of study participation were also excluded. Consolidated Standards

of Reporting Trials (CONSORT) diagram for the Benchmarking Study and Replication Study is

provided in **Figure 3** (bottom), and participant exclusions are detailed in the Results section.

Demographic data including age, sex, APOE4 allele status, MOCA and GDS for the

Benchmarking Study, Replication Study, and Combined Studies are provided in **Supplemental**

**Table 1.**

1034

*Study Protocol*

As shown in the study schematic (**Figure 3**, top), this is a cross-over study in which participants

took part in two overnight study visits, one undergoing normal sleep and the other undergoing

overnight sleep deprivation, at a 2-4 week interval. Each overnight study visit consisted of three

study periods beginning at 1900 hrs, 0700 hrs, 1330 hrs separated by two intervals – an

overnight interval (2300-0630 hrs), and a morning interval (0800-1130 hrs).

1041

Benchmarking Study: Beginning with arrival to the study suite at 1900, participants underwent a

blood draw for APOE genotyping and assessment of amyloid $\beta$ and tau biomarkers ($A\beta_{1-40}$, $A\beta_{1-42}$,

$_{42}$, phospho-tau181, phosho-tau217, non-phospho-tau181, non-phospho-tau217; $C_2N$

Diagnostics[65-67]) and 60 min of non-contrast magnetic resonance imaging (MRI) scanning

(sequences detailed below). On completion, participants were instrumented for commercial

polysomnography (PSG, Philips Respironics Alice 6 LDx Diagnostic Sleep System) that

included a 10-20 EEG montage with electro-oculogram (EOG) and submental electromyogram

(EMG). Electrode impedances were required to be below 5 k$\Omega$. Participants were last

instrumented with the Investigational Device, and device electrode impedances required to be

below 5 k$\Omega$.

1052

The Overnight interval lasted from 2300-0630 hrs the following morning. To support study

planning, participants were randomized to undergo either normal sleep or sleep deprivation for

their initial overnight visit following completion of their informed consent, however this

information was not shared with the participants. To reduce likelihood of preparation bias on the

part of participants (i.e. altering sleep schedules or taking naps in anticipation of sleep

deprivation visits) participants were not informed of their initial visit assignment until 4pm the

day of their arrival.  Both PSG and Investigational Device recordings took place continuously

throughout the Overnight interval. Throughout the overnight period, sleep-assigned participants

were allowed to sleep normally without interruption. Participants assigned to the sleep

deprivation were monitored by study staff to ensure adherence to the sleep deprivation protocol.

1063

Between 0700-0745 hrs the next morning, all participants were administered a cognitive battery

that included the 5-minute psychomotor vigilance test for sustained attention[68,69], symbol-digit

modality test of processing speed, trail making test part A and part B for assessing executive

function[70], and digit span forward test of working memory[71]. Following the cognitive battery,

participants underwent a blood draw for amyloid $\beta$ and tau biomarkers and a second non-

contrast MRI scanning session (denoted $T_0$ in Results section). Immediately following the

second non-contrast MRI scan, participants underwent intravenous gadolinium-based contrast

agent (GBCA) injection (Gadavist, 0.1 mmol/kg), followed by T1- and T2-weighted contrast-

enhanced MRI scans 7-10 min after GBCA injection (denoted $T_{10}$ in Results section).

1073

Participants were escorted back to the study suite where they were re-instrumented with the

commercial PSG and the Investigational Device. The Morning Interval ran from 0800 to 1130.

Participants who assigned to the sleep condition in the Overnight Interval were required to

remain awake and were monitored by study staff to ensure adherence; those assigned to the

sleep deprivation condition in the Overnight were allowed to sleep. During this interval both the

PSG and Interventional Device recorded data. The third assessment period commenced at the

end of the Morning Interval. Participants underwent a final blood draw for amyloid $\beta$ and tau

biomarker assessment and then had a third MRI scanning session, including non-contrast

sequences and T1- and T2-weighted contrast-enhanced sequences at approximately 4 hrs

post-GBCA injection (denoted $T_{240}$ in Results section).

1084

Replication Study: The Replication protocol was an abridged version of the Benchmarking

protocol. The inclusion/exclusion criteria were identical to the Benchmarking study except for

the lower age cut-off. Participants were similarly randomized to a night of sleep or a night of

sleep deprivation on their first visit, with a crossover to the alternative sleep/sleep deprivation

assignment on their second visit. The protocol for the Replication Study was identical to that of

the Benchmarking Study excepting that 1) Participants did not undergo commercial PSG, sleep

was assessed by Investigational Device EEG; 2) Participant sleep deprivation adherence in the

Overnight Interval was assessed retrospectively using the sleep EEG; 3) The cognitive battery

did not include the digits forward working memory test; 4) Participants underwent only non-

contrast, and not contrast-enhanced MRI.

Cognitive Assessments: The 5-minute PVT from Texas A&M University System CSE[72] and

digits forward recall from Cambridge Cognition[71] were administered on an iPad. The paper-

based SDMT from Western Psychological Services[73], the TMT A and TMT B[74], were

administered by a clinical coordinator trained in administering these tests. The cognitive battery

was administered in a quiet room with minimal distractions on the morning following sleep/wake

and prior to the neuroimaging and phlebotomy. The administration of each test was preceded by

the corresponding practice test. We have included a description of these tests within the overall

protocol for completeness. The results of these cognitive tests, and their relationship to

Investigational Device outputs, sleep parameters, fluid biomarkers, and MRI measures of

glymphatic function will be reported elsewhere.

Plasma Biomarkers: The APOE genotyping, amyloid $\beta$ and tau plasma biomarkers were

analyzed using mass spectrometry by $C_2N$ Diagnostics[75]. The sample collection procedure was

provided by $C_2N$ Diagnostics. Venipuncture and blood draw from the antecubital fossa were

performed using a 22-gauge butterfly needle to minimize red blood cell hemolysis. A total of 10

ml of blood was drawn into a $K_2$ EDTA Vacutainer. The blood was centrifuged for 15 min using a

swinging bucket rotor at 500-700 x g with the brake on. Immediately after centrifugation, four 1.0

mL plasma samples were aliquoted into four Sarstedt 2.0 ml Micro Tube without disrupting the

plasma/cell interface when transferring plasma. A calibrated air-displacement hand-held pipette

with a polypropylene pipette tip was used. After aliquoting plasma into the Sarstedt Micro

Tubes, the tubes were immediately capped and frozen at -40$^{\circ}$C. When the tubes were ready to

be shipped to $C_2N$ Diagnostics, they were packed into a plastic zip-lock bag with plenty of dry

ice, placed in an absorbent towel and cryobox, and express couriered to $C_2N$ Diagnostics

priority overnight. In the present report, we utilize APOE4 allele status as a covariate in our

analysis, and we have included a description of plasma biomarker assessment within the overall

protocol for completeness. However, the fluid biomarker levels, and their relationship to

Investigational Device outputs, sleep parameters, cognitive tests, and MRI measures of will be

reported elsewhere.

1124

*Magnetic Resonance Imaging Approach*

MRI scanning at The Villages site was conducted on a 3T Siemens Vida system at Lake

Medical Imaging, while scanning at the University of Washington site was conducted on a 3T

Philips Ingenia Elition X at the Diagnostic Imaging Sciences Center. In the present report, to

define the relationship between brain $R_P$ and glymphatic function, we utilize CE-MRI from

Benchmarking Study participants following the overnight sleep condition. We have included a

description of the other MRI-based approaches within the overall protocol for completeness.

However, the relationship between these different MRI measures of glymphatic function,

Investigational Device outputs, sleep parameters, cognitive tests, and fluid biomarker levels will

be reported elsewhere.

1135

Contrast-Enhanced MRI: Contrast-enhanced MRI involves intravenous administration of a

Gadolinium chelate that shortens T1, T2, and T2* relaxation parameters of the tissue it

traverses through. Specifically, in this study, shortening of the T1 relaxation parameter

enhances MRI signal that is proportional to the amount of Gadolinium and its characteristic

relaxivity. Gadolinium passes quickly through the cerebral and peripheral vasculature within the

first 5-30 minutes. A fraction of the contrast enters the CSF and ISF[14,15] over many hours and

finally almost 99% of the contrast exits the body by renal clearance. The passage of intravenous

GBCA from the vasculature to the CSF and ISF was measured in terms of a delayed signal

enhancement at approximately 4 hours after administration. Two prior studies have shown that

delayed enhancement following contrast injection between 3 and 6 hours is indicative of solute

(in this case, GBCA) transport via the CSF-ISF glymphatic exchange[14,15].  At the Villages®, we

performed 3D T1-weighted magnetization-prepared rapid acquisition with gradient echo

(MPRAGE) with TR/TI/TE = 2300/900/2 ms, resolution = $1\times1\times1$ mm$^3$, field-of-view =

$256\times256\times208$ mm$^3$, total acquisition time = 5:12 min before contrast injection. The post-contrast

MRI image ($T_{10}$) was acquired approximated 7-10 minutes after contrast injection and its

acquisition was identical to the pre-contrast image. A second post-contrast scan was acquired

about 4 hours ($T_{240}$) later using identical imaging parameters.

1153

Structural MRI: Structural T1 MRI was used for classifying the brain tissue into lobar gray

matter, lobar white matter, and CSF as well as for segmenting regions-of-interests including the

hippocampus, sagittal sinus, internal carotid arteries, lateral ventricle, and subarachnoid space.

The T1 images were also used for registration purposes for all other imaging modalities. The T1

images were used for determining PVS morphometry[76,77].  Scanning parameters for the

Benchmarking Study are identical to the contrast-enhanced MRI. Scanning parameters for the

Replication Study were TR/TI/TE = 12/1000/4.5 ms, resolution = $0.8\times0.8\times0.8$ mm$^3$, field-of-view

$= 256{\times}240{\times}166$ mm$^3$, total acquisition time = 5:24 min. Since inclusion of T2 MRI significantly

improves PVS detection, a T2 MRI with TR/TE = 3200/561 ms, resolution = $0.8{\times}0.8{\times}0.8$ mm$^3$,

field-of-view = $256{\times}240{\times}166$ mm$^3$, total acquisition time = 4:32 min was also added.

1164

<u>Intravoxel Incoherent Motion MRI:</u> Intravoxel incoherent motion (IVIM) MRI is a multi-shell

diffusion imaging approach to measure water movement at different scales of distance and time.

Glymphatic transport includes movement of CSF in the subarachnoid space and the interstitium

at a slow speed (~1 mm/s) over large distances (~100-200 um)[1,30,40]. This perivascular

movement of CSF through the subarachnoid compartment is upstream of its exchange with the

ISF along the penetrating intraparenchymal vasculature and hence could serve as an important

correlate of glymphatic function[78]. The imaging parameters for the Benchmarking Study were:

TR/TE = 5500/124 ms, resolution = $1{\times}1{\times}5$ mm$^3$, field-of-view = $250{\times}250{\times}150$ mm$^3$, parallel

imaging factor = 2, multi-band factor = 3, fat suppression with Spectral Presaturation with

Inversion Recovery (SPIR), b values = 0, 50, 100, 150, 200, 250, 300, 350, 400, 500, 700, 800,

and1000 s/mm$^2$, and total acquisition time = 7:01 min. The b = 0 s/mm$^2$ was acquired with

reverse phase encoding to correct for field distortions. The imaging parameters for the

Replication Study were TR/TE = 2978/90 ms, resolution = $1{\times}1{\times}5$ mm$^3$, parallel imaging factor =

2.2, field-of-view = $230{\times}196{\times}115$ mm$^3$, fat suppression with SPIR, b values = 0,

10,40,80,100,150,200, 300,500,700, 800, 900,1000 s/mm$^2$, and total acquisition time = 8:08

min. A Split echo (SPLICE) acquisition was used to eliminate the need for distortion correction.

1181

<u>Multi-Echo, Multi-Delay Arterial Spin Labeling (ASL) MRI:</u> Multi-echo, multi-delay ASL measures

perfusion and time for exchange of water across the endothelium. This time metric is dependent

on perfusion, endothelial permeability, and the glial vascular unit including the AQP4 water

channels that are critical to the perivascular CSF-ISF exchange[78,79]. This protocol was

implemented only for the Replication Study as a Hadamard-encoded ASL acquisition, TR/TE =

5000 ms, resolution = $1\times1\times5$ mm$^3$, field-of-view = $230\times196\times115$ mm$^3$, post labeling delay = 650,

950,1210,1510,2083,2383 ms with background suppression, label duration = 3400 ms, and TE

= 0,40,80, 120 ms. Total acquisition time = 12:40 min. A conventional arterial spin labeling

(ASL) protocol was implemented in the Benchmarking Study due to the lack of availability of the

multi-echo component. The parameters were: TR/TE = 4420/22 ms, resolution = $1.7\times1.7\times4$

mm$^3$, field-of-view = $220\times220\times96$ mm$^3$, post labeling delay = 500,

900,1000,1100,1200,1400,1600,1800, label duration = 1800 ms. Total acquisition time = 2:37

min. The sequence was acquired twice. A reference M0 images was acquired in both studies

with identical parameters but without background suppression or labeling.

1196

<u>Fast Functional MRI:</u> A sub-second functional MRI sequence was implemented to separate and

regress physiological noise (cardiac and respiratory signals) as well as to capture slow CSF

oscillations in the ventricles[80]. The protocol for the Benchmarking Study was TR/TE = 400-

500/30 ms, resolution = $3.6\times3.6\times3.6$ mm$^3$, flip angle = 70°, multi-band factor = 4, field-of-view =

$230\times2430\times101$ mm$^3$, fat suppression, no. of volumes = 365 using SPIR, total acquisition time =

2:37 min. Heart rate and respiration were monitored using the BIOPAC MR160 and

synchronized with MRI acquisition. The Replication Study used a gradient-echo, echo planar

imaging sequence with TR/TE = 400-500/30 ms, resolution = $3\times3\times4$ mm$^3$, flip angle = 42°, multi-

band factor = 6, field-of-view = $240\times240\times123$ mm$^3$, slice gap = 0.4 mm, fat suppression using

SPIR, no. of volumes = 450, total acquisition time = 3:00 min. Two single volume, spin echo

acquisitions were also acquired with opposite phase encoding to allow for distortion correction.

Heart rate and respiration were monitored using the sensors built into the Philips scanner and

synchronized with MRI acquisition. Glymphatic CSF-ISF exchange is at least partly driven by

vasomotion, which may be reflected by periodic motion in the CSF spaces. This CSF motion

correlates well with sleep stages, with power of the slow CSF oscillation increasing from

wakefulness to the N1 and finally to the N2 stage[80].

1213

<u>Phase-Contrast MRI:</u> The phase contrast MRI is used to quantify CSF efflux from the Aqueduct

of Sylvius. The peristaltic motion of CSF at the Aqueduct is measured by gating the MRI signal

to the participants and calculating the CSF motion into and out of the brain over a cardiac

signal. Variations in CSF efflux velocity appear to follow the cardiac and respiratory signals and

may impact glymphatic CSF-ISF exchange. The Benchmarking Study protocol for this MRI was

the following: a single slice acquisition perpendicular to the Aqueduct of Sylvius, TR/TE = 21/6.6

ms, resolution = $30.6 \times 0.6 \times 6$ mm$^3$, flip angle = $10°$, 40 phases per cardiac cycle, and velocity

encoding for 12 cm/s, total acquisition time: 2:00 min. The Replication Study protocol included

the following: a single-slice acquisition perpendicular to the Aqueduct of Sylvius, TR/TE = 12/7.9

ms, resolution = $30.6 \times 0.6 \times 4$ mm$^3$, flip angle = $10°$, 15 phases per cardiac cycle, and velocity

encoding for 12 cm/s, total acquisition time: 2:02 min

1225

*Statistical Approach*

The Benchmarking study was designed to have 80% power at a significance level of 5% to

detect a low-to-moderate correlation $r$ ($r$=0.5) between the device measurements and CE-MRI

measurement of glymphatic function. The Replication study was designed to have 80% power

at a significance level of 20% to detect a low-to-moderate correlation $r$ ($r$=0.5) between the

device measurements and non-contrast MRI measurement of glymphatic function and to detect

overnight sleep/wake differences in brain parenchymal resistance.

1233

The parenchymal resistances $R_P$ computed from each EIS scan from the device were

normalized to the sleep/wake onset values to allow comparison across visits and participants.

To reduce measurement variability of the sleep/wake onset value, the value was inferred from a

linear regression to the initial $R_P$ values. The overnight change in $R_P$ per participant visit was

taken as the average of the normalized values for that visit. For example, a value of 1 indicated

that there was no overnight change from the onset value and a value of 0.8 indicated a 20%

overnight reduction from onset. A Student's T-test group comparison between sleep/wake visits,

group mean and SD were calculated.

1242

Contrast-enhanced MRI of sleep-related glymphatic function was analyzed using a random

intercept linear mixed effect model (R, lme in the lmne package). Glymphatic function was

defined by measuring brain parenchymal contrast enhancement, the % change in T1-weighted

signal intensity between 10-240 min post-GBCA injection ($100\% * (T_{240}-T_{10})/T_0$) at each of eight

regions of interest (ROIs): frontal cortical gray and white matter, parietal cortical gray and white

matter, temporal cortical gray and white matter, and occipital gray and white matter. Only sleep

visits were analyzed leading to a one level of grouping, the eight ROIs, for the participant sleep

visit. All models included regressors in the mixed model for the $T_{10}$-$T_{240}$ change in blood signal

within the internal carotid artery, and the $T_{10}$-$T_{240}$ change in CSF signal within the cerebral

lateral ventricles to compensate for the influence of vascular and CSF contrast on parenchymal

enhancement. Potentially confounding biological variables age, gender, and APOE ε4 status

were also included in all models.

1255

To evaluate different sleep-related contributions to glymphatic function, overnight changes from

sleep onset for each of the four recorded EEG relative band powers (delta, theta, alpha, beta)

and for HR were computed. The recorded values were normalized to their respective value at

sleep onset and a single statistic, the average of the overnight normalized values, computed per

participant visit. The four hypnogram sleep stages (N1, N2, N3, REM) and WASO were each

summed into single total sleep stage durations and total WASO duration per participant visit.

The device $R_P$ normalization and averaging has been previously described. Models were run

separately for each of the four EEG relative band powers (delta, theta, alpha, beta), for each of

the four hypnogram sleep stages (N1, N2, N3, REM), for WASO, for HR and for device $R_P$. Two

full models were then fit to the data, with the EEG band power and the hypnogram sleep stages

separated into distinct models because of collinearity across those predictors. The variance

inflation factor (R 'vif' function from the 'car' package) was used to test for predictor collinearity

using a threshold of 5. The EEG powerbands included were limited to delta, theta and beta

because of collinearity among the four relative band powers. HR and the device $R_P$ were

included in both full models. Each full model was reduced to a selected model using backward

elimination of predictors with a threshold Wald's p-value of 0.05.

1272

Model selection stability, or robustness of the selected model to perturbations in the dataset,

was tested using resampling-based multi-model inference[29]. The dataset was bootstrapped

resampled with replacement to generate 500 bootstrapped datasets. For each of these datasets

the two full models were estimated and reduced to a selected model using backward

elimination. The bootstrap inclusion frequency (the percent of bootstrap datasets that included

the predictor), the RMSD ratio (the RMSD of the predictor bootstrap estimate divided by the

standard error of that coefficient in the full model and expressing the variance inflation or

deflation caused by variable selection), the relative conditional bias (quantifying the variable-

selection-induced bias to expect if a predictor is selected) and the bootstrap median of each

predictor coefficient were reported.

1283

1284 The analyses of device $R_P$ values with EEG band powers, heart rate and hypnogram staging

1285 were performed on the overnight sleep recordings. Analyses were grouped into REM sleep and

1286 NREM sleep (N1, N2 and N3). The device resistances were computed repeatedly throughout

1287 the night from each EIS scan. During sleep recordings, these data were non-stationary. After

normalization to sleep onset as previously described, first-order differences $\Delta R_P$ and $\Delta X$ for X

one of the EEG band powers or HR were incorporated into individual random intercept linear

mixed models to evaluate their relationship. Threshold regression models were used in the

linear mixed model. A custom estimation procedure described in **Supplemental Information**

was used to jointly estimate the threshold regression for the full positive and negative range of

the predictors. The hinge threshold model was analytically reduced to estimation by linear

regression which allowed it to be used in a random intercepts linear mixed effects regression

model. The autocorrelation function and augmented Dickey Fuller tests were used to confirm

stationarity of the differenced variables $\Delta R_P$ and $\Delta X$ and also of the fitted model residuals (R,

acf and adf functions).

In addition to the analyses of $\Delta R_P$ and $\Delta X$ for X one of the EEG powerbands or HR during REM

sleep and NREM sleep, these were analyzed at hypnogram transitions NREM to REM, REM to

NREM, sleep to wake and wake to sleep. The analysis was similar, using threshold regression

models in a random intercept mixed linear model.

Univariate outliers were trimmed at the 0.5 and 99.5 percentile. For multivariate analysis, the

Mahalonobis distance was computed and outliers trimmed at the 0.5 and 99.5 percentile of the

Mahalonobis distance. All regressions were adjusted for potential confounding effects of age,

sex and APOE genotype. All tests were considered significant at a 5% level if the 95%

confidence interval (CI) did not contain the null hypothesis. All statistical analyses were

performed in R version 4.2.1 (2022-06-23) or Graphpad Prism 8.0.0.

We reported the pooled findings of the Benchmarking and Replication study for both the

investigational device transcranial resistance measurements and EEG parameters.

**SUPPLEMENTAL INFORMATION**
***Supplemental 1: Analysis of device EEG and commercial polysomnography***

The single derivative device EEG was validated against the commercial PSG (Philips

Respironics Alice 6 LDx Diagnostic Sleep System) in participants that underwent concurrent

device and PSG sleep recording as part of the Benchmark study. Both hypnogram sleep staging

and sleep parameters were validated using a confusion matrix between the device prediction

and the PSG prediction both per participant and pooled across participants. Prediction metrics

computed included sensitivity, specificity, precision, accuracy and F1 score. The device EEG

with EOM and the PSG C3-A2, C4-A1 derivatives were individually input into the automated

hypnogram scoring (Python yasa 0.6.3 *SleepStaging*). Manual scoring of the PSG by a sleep

physician (YC) was used as the gold-standard. The results of these comparisons are provided

in **Supplemental Table 6.**

1327

***Supplemental 2: Threshold regression model and estimation***

Threshold regression models were fit on data that spanned the full positive and negative range

of abscissa values. These models are defined by a positive turning point $t_p \geq 0$ where for $x \geq$

$t_p$ the regression line goes from $f(x) = 0$ to $f(x) = m_p(x - t_p)$ and a negative turning point

$t_n \leq 0$ where for $x \leq t_n$ the regression line goes from $f(x) = 0$ to $f(x) = m_n(x - t_n)$. These

models can be reduced to linear regression. First transform the data $(x, y) \rightarrow (w, y)$ were

1334
$$w = \begin{cases} x - t_n \; if \; x \leq t_n \\ 0 \; if \; t_n < x < t_p \\ r(x - t_p) if \; x \geq t_p \end{cases}$$

For values of $t_p$, $t_n$ and $r$, a least squares estimator can be used to fit a linear model to the

transformed data values $(w, y)$. With $r = \frac{m_n}{m_p}$, the transformed data is linear, through the origin

and has slope $m_n$. When $r = 1$ both slopes are identical; for $r \neq 1$ the positive half-space slope

equals the regression estimate multiplied by $r$. Hence, for $r < 1$ the positive half-space slope is

less than the negative half-space slope and for $r > 1$ the positive half-space slope is greater

than the negative half-space slope.

1341

The linear fit was estimated using an F-statistics, the ratio of the explained variance (due to the

model) and the unexplained variance (residuals). Grid search over the parameter space $t_p$, $t_n$

and $r$ was carried out and the values that minimized the mean sum of squared residuals (and

hence maximized the F-statistic) was reported[81]. To avoid edge effects, $t_p$ and $t_n$ were set to

*±1.5* standard deviations[82]. Random intercept linear mixed models were similarly fit to the

transformed data and grid search used to solve for the parameters that minimized the mean

sum of squared residuals for the fixed effects. The autocorrelation function was used to confirm

no residual autocorrelation following model estimation and fit.

1350

1351

***Supplemental 3: Physiological basis for electrical impedance spectroscopy change with***

***glymphatic function.***

In normal adult men (women) between the ages of 60-86 years, the GM, WM and total

intracranial volumes (TIV) are 614.3 ± 60.1 (562.6 ± 50.1 ml), 534.0 ± 57.2 ml (476.6 ± 44.7 ml)

and 1603.0 ± 133.0 ml (1425.9 ± 109.0 ml)[83]. Average adult cerebral blood flow (CBF) is

approximately 750 ml/min or 12.5 ml/sec. Assuming HR of 60 bpm, 12.5 ml of blood injected

into the brain causes an approximate 50 mΩ decrease in the device IPG sampled at 80 kHz

(see for example **Figure 2d**, IPG-Impedance Plethysmograph data taken from a female study

participant). At 80 kHz, EIS measures the extracellular compartment and most of the

intracellular compartment. Thus, the 12.5 ml increase in blood volume, representing a

12.5/1425.9 = 0.88% change in TIV, would be measured as a 50 mΩ decrease in resistance by

EIS.

1364

At low frequencies, EIS measures changes in extracellular volume. The interstitial cortical

volume fraction α in awake rodents has been shown to be 14.1% and in sleeping rodents 23.4%

whereas the tortuosity λ of the interstitial space remained unchanged across sleep and wake[2,84].

This suggests that in rodents, the sleep-induced volume expansion of the interstitial space

occurs from a change in the cross-sectional area and not length. This is noteworthy because

resistance of a conductor is proportional to $\frac{l}{A}$ where $l$ is the length and $A$ the cross-sectional

area. Therefore, the increase in interstitial space fluid with glymphatic function will increase the

cross-sectional area of the interstitial space channels and proportionally decrease the

transcranial electrical resistance. In humans, the measurements range from 15-20%[85] but

changes with sleep/wake have not been assessed. Using the rodent data as a proxy to what we

might expect in humans, we would expect a 66% increase in interstitial volume with sleep to

occur from of a 66% increase in cross-sectional area of the interstitial channels. The remaining

extracellular compartment volumes contributing to the resistance at low EIS frequencies are

CSF and blood plasma that occupy a total volume comparable to the awake interstitial volume.

Therefore, the net extracellular compartment volume increase, or effective cross-sectional area

increase, with sleep is 33%. Using the IPG relationship between fluid volume change and

transcranial impedance, a 0.88% increase in fluid volume was measured as a 50 mΩ decrease

in transcranial electrical resistance implying that a 33% volume increase would be measured as

an 1875 mΩ decrease. This analysis uses the conclusion that the interstitial volume increase of

glymphatic function is an increase in the interstitial channel cross-sectional area and similarly

the assumption that the intravascular volume increase of cardiac output is from an increase in

the intravascular cross-sectional area. The preceding analysis assumed a 66% increase in

interstitial volume fraction as seen in rodents. Assuming a smaller 25% volume fraction increase

and using the same analysis, we would expect a 710 mΩ decrease in transcranial resistance

with sleep.

1390

***Supplemental 4: Benchtop and agar phantom characterization of electrodes and device.***

Electrodes were characterized according to the ANSI/AAMI EC12 standard for AC impedance,

DC offset voltage, combined offset instability and internal noise, and bias current tolerance[57].

Defibrillation overload recovery was not tested as it is not relevant to the present application.

Pairs of electrodes were immersed in a 140 mM NaCl solution, facing each other and separated

by 3-4 mm. AC impedance at 10 Hz was measured using a multifunction DAQ module (Analog

Discover 2, Digilent) configured for 2-point impedance measurement. An excitation voltage of

100 millivolts peak-to-peak (mVpp) and a 10 kΩ series resistor guaranteed a maximum current

of 10 microamps peak-to-peak (μApp). DC offset voltage was measured with a Fluke 87V

multimeter. Offset instability and internal noise were measured over five minutes using a 24-bit

digitizer module (ADS1299EVM, Texas Instruments, 67 nV resolution) sampling at 2000

samples per second, calibrated using a Keysight EDU33212A Signal Generator. Recorded data

was subsequently filtered with a 0.15-100 Hz first order bandpass (simulating EC12 filtering) or

the 0.3-50 Hz EEG bandpass filter described in **Signal Processing –**

**Electroencephalography**. Peak-to-peak values over the 5-minute period are reported. Bias

current tolerance was measured with a multifunction DAQ module using its 14-bit digitizer

(0.32 mV resolution) as data logger (sampling every 10 seconds for 8 hours), and its power

supply to apply 200 nA DC across the pair of electrodes (2 V across a 10 MΩ resistor in series).

The maximum voltage deviation relative to the initial offset voltage before current application is

reported. All results are found in **Supplemental Table 7**.

1411

Benchtop validation of the investigational device EIS compared the measured to the theoretical

resistance and reactance at each frequency on a circuit model of brain parenchymal impedance

(the load) with separate models for each of the four electrode impedances. The circuit diagram

for these benchtop measurements is shown in **Supplemental Figure 2.** The load was modelled

using 2R1C parallel circuit and the four electrode-skin interfaces were modeled by individual

2R1C circuits with a charge transfer resistance in parallel to a double layer capacitance that was

in series with a resistor embodying the electrolyte and stratum corneum resistance. The

resistance and capacitance values for the load were based on observed participant resistance

and reactance over the EIS frequencies. Two sets of parameters for the electrode impedance

models were used, a low-impedance model and a high-impedance model. These were selected

to cover the observed range of subject electrode impedances over the range of EIS frequencies.

The parameters for the complete set of benchtop tests are found in **Supplemental Table 8** and

included (i) calibration measurements of purely resistive loads, (ii) calibration of a 2R1C load

varying the parallel resistor $R_s$ to simulate changes in the interstitial space resistance, and (iii)

calibration of a fixed 2R1C load while varying the electrode impedances at each electrode

between low and high impedance settings to test the sensitivity to expected variations during

use. The absolute error between the measured and theoretical resistance and reactance for the

benchtop tests are reported in **Supplemental Table 9** and in **Supplemental Table 10**,

respectively. The measured impedances reported were rotated by multiplying by the factor

$e^{-j\omega T}$ with the value $T$ chosen so that the reactance at 256kHz was zero[59]. The absolute error of

the resistance reveals a systematic positive bias implicating contributions to the resistance in

the device or benchtop setup that were not fully compensated by the device calibration. For the

measurements of the 2R1C benchtop tests, the resistance bias is 0.278 Ω and the bias un-

adjusted and adjusted RMSE are 0.321 Ω and 0.144 Ω, respectively. The reactance did not

show a systematic bias. The RMSE of the reactance for the 2R1C benchtop tests is 0.128 Ω.

Because we are interested in the dispersion of the resistance over frequencies, or the difference

between the resistance at a low frequency and at a high frequency, the bias cancels out. Using

the signal processing pipeline to fit the Debye model, **Supplemental Table 11** reports the

dispersion prediction error from theoretical value at each frequency relative to 128 kHz.

Reported values are for the 2R1C electrode impedance sensitivity tests. The 1 kHz minus

128kHz dispersion is representative of the parenchymal resistance $R_P$ computed from the

difference between the extrapolated DC resistance and the infinite frequency resistance. This

dispersion had an RMSE of 0.147 Ω approaching the bias-adjusted RMSE of the 2R1C

benchtop tests in **Supplemental Table 9**, and represents a 3.1% measurement error in the

theoretical dispersion value of 4.766 Ω.

1447

The device EIS showed the accuracy needed to reliably measure a single $R_P$ value but to

evaluate glymphatic function it needs to detect changes in $R_P$. These changes are small by

comparison to the absolute value of $R_P$. As discussed, the overnight decrease ranges between

500 mΩ and 2000 mΩ. With the current time-multiplexing settings, the device completes

approximately 84 scans over a 7-hour night of sleep, or 6 to 23 mΩ average decrease between

scans. The statistical models used in the analysis of the Benchmarking Study and Regression

Study required significance testing of the mean change in $R_P$ between sleep and wake, and

testing significance of predictors of $R_P$ in linear mixed models. These tests depend on the SD of

the Debye model dispersion estimate which for the electrode impedance sensitivity tests was

0.113 Ω, slightly less than the bias-adjusted RMSE. **Supplemental Table 12** shows that the

minimum change in $R_P$ with 25 and 100 EIS scans that is statistically significant is 44 mΩ and

22 mΩ, respectively. Note that during sleep, $R_P$ decreases with glymphatic function and

therefore each measurement arises from a distribution with a different mean but the same SD

$\sigma$. Using the linearity of expectation and statistical independence of each $R_P$ measurement, the

standard error of the mean of $R_P$ is $\frac{\sigma}{\sqrt{n}}$ for $n$ samples. Using the Fisher transform[86] to solve for

the minimum significant correlation detectable at a given sample size, **Supplemental Table 11**

reports that weak to moderate correlations of $R_P$ with predictors will be significant at 100 and 25

EIS scans, respectively. These estimates are optimistic since not all sources of error are

accounted by the electrode impedance sensitivity tests.

1467

1468  Agar phantom testing over 12 hours was used as a final quality check for each fully assembled

1469  device. These tests measured the device combined noise level from the electronics,

1470  electrochemical interfaces between the electrodes, EEG gel and agar. **Supplemental Figure 3**

1471  shows the device periodogram, EEG recording and power spectral density from an agar

1472  phantom test.

1473

1474  **Data availability**

1475  The data supporting the results in this study are available from the corresponding author with

1476  Institutional Review Board approval and Data Use Agreement permitting non-commercial use of

1477  data for independent validation, publication and sharing of new findings.

1478

1479  **Code availability**

1480  Code used for the analysis and to produce figures are available upon reasonable request to the

1481  corresponding author.

1482

1483

1484 **Supplemental Table 1. Demographic, genetic and psychometric results of the**
1485 **Benchmarking Study, Replication Study and Combined Study.**
1486

|  | Benchmarking Study | Replication Study | Combined Study |
|---|---|---|---|
| **N** | 30 | 14 | 44 |
| **Age ± SD (Range)** | 61.8 ± 2.7 (56, 66) | 55.6 ± 4.6 (49, 63)* | 59.8 ± 4.4 (49, 66) |
| **Female (Male)** | 14 (16) | 7 (7) | 21 (23) |
| **APOEe4 (not APOEe4)** | 8 (22) | 5 (9) | 13 (31) |
| **MoCA ± SD (Range)** | 27.8 ± 1.1 (26, 30) | 28.6 ± 1.2 (26, 30) | 28.1 ± 1.2 (26, 30) |
| **GDS ± SD (Range)** | 0.7 ± 1.1 (0, 4) | 0.6 ± 1.2 (0, 4) | 0.7 ± 1.1 (0, 4) |

1487 Montreal Cognitive Assessment, MoCA; Geriatric Depression Scale, GDS. *$P<0.001$
1488 Benchmarking vs. Replication Study, unpaired t-test.

1489 **Supplemental Table 2. EEG band power, hypnogram, and $R_P$ as individual predictions of parenchymal contrast**
1490 **enhancement when added to the null model following overnight sleep.**
1491

| | Predictor | Estimate | 95% CI | P Value | LRT | LRT P Value |
|---|---|---|---|---|---|---|
| **Predictors Added to Null Model** | **Delta Band Power** | 19.121 | (5.482, 32.760) | **0.007** | 7.50 | **0.006** |
| | **Theta Band Power** | -3.755 | (-11.982, 4.473) | 0.378 | 0.81 | 0.368 |
| | **Alpha Band Power** | -7.279 | (-12.264, -2.294) | **0.005** | 8.12 | **0.004** |
| | **Beta Band Power** | -5.329 | (-7.786, -2.873) | **<0.001** | 17.49 | **<0.001** |
| | **Heart Rate** | -21.624 | (-49.814, 6.566) | 0.139 | 2.28 | 0.131 |
| | **WASO Time** | -0.003 | (-0.045, 0.038) | 0.881 | 0.02 | 0.879 |
| | **N1 Sleep Time** | -0.128 | (-0.213, -0.042) | **0.004** | 8.46 | **0.004** |
| | **N2 Sleep Time** | -0.031 | (-0.071, 0.009) | 0.139 | 2.28 | 0.131 |
| | **N3 Sleep Time** | 0.025 | (-0.024, 0.075) | 0.322 | 1.02 | 0.313 |
| | **REM Sleep Time** | 0.031 | (-0.023, 0.086) | 0.268 | 1.28 | 0.258 |
| | **Parenchymal Resistance** | -38.080 | (-61.348, -14.812) | **0.002** | 10.15 | **0.001** |
| | | | | | | |
| **Null Model Fixed Effects** | **Blood CE** | 10.29 | (5.45, 15.13) | **<0.001** | – | – |
| | **CSF CE** | 148.48 | (123.40, 173.56) | **<0.001** | – | – |
| | **Age** | -1.31 | (-1.91, -0.71) | **<0.001** | – | – |
| | **Male Sex** | -2.69 | (-5.42, 0.063) | 0.060 | – | – |
| | **APOE ε4** | -3.29 | (-6.50, -0.091) | **0.048** | – | – |
| | | | | | | |
| **Null Model Random Effects** | $\sigma^2$ | 70.50 | – | – | – | – |
| | $\tau_{00}$ ROI | 12.60 | – | – | – | – |

1492 Wake After Sleep Onset, WASO; Rapid Eye Movement, REM; Confidence Interval, CI; Likelihood Ratio Test, LRT. **Bolded P values**
1493 **reflect significant associations at P < 0.05**. Likelihood ratio test taken between null model and model with predictor.
1494

1495 **Supplemental Table 3. Multivariate models of morning brain parenchymal contrast enhancement using overnight and**
1496 **morning Rp, HR and EEG hypnogram predictors.**
1497

| Predictor Period | Fixed Effect Predictors | Full Model | | | Selected Model | | | Bootstrap Analysis | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | | Estimate | CI | p | Estimate | CI | p | Bootstrap Inclusion Frequency (%) | RMSD Ratio | Relative Conditional Bias (%) | Bootstrap Median |
| Overnight Sleep Opportunity | Blood CE | 0.87 | -5.26, 7.00 | 0.786 | – | – | – | 11.6 | 2.14 | 386.83 | 0 |
| | CSF CE | 221.86 | 185.38, 258.34 | **<0.001** | 225.82 | (208.18, 243.47) | **<0.001** | 100.0 | 0.94 | 0.01 | 225.13 |
| | Age | -0.30 | -0.82, 0.23 | 0.286 | – | – | – | 39.8 | 1.86 | 107.95 | 0 |
| | Male Sex | -2.70 | -5.77, 0.36 | 0.094 | – | – | – | 41.8 | 1.07 | 53.57 | 0 |
| | APOE ε4 | -4.60 | -7.86, -1.35 | **0.008** | -5.33 | (-8.34, -2.31) | **0.001** | 81.6 | 0.98 | 16.33 | -4.77 |
| | $R_P$ | -76.16 | -99.79, -52.53 | **<0.001** | -67.17 | (-87.78, -46.56) | **<0.001** | 100.0 | 1.16 | -5.30 | -72.57 |
| | REM Time | 0.16 | 0.08, 0.24 | **<0.001** | 0.16 | (0.09, 0.23) | **<0.001** | 99.0 | 1.06 | 1.30 | 0.16 |
| | N1 Time | -0.30 | -0.43, -0.16 | **<0.001** | -0.32 | (-0.43, -0.21) | **<0.001** | 98.8 | 1.09 | 0.95 | -0.31 |
| | N2 Time | -0.10 | -0.14, -0.05 | **<0.001** | -0.10 | (-0.15, -0.06) | **<0.001** | 98.0 | 0.80 | -1.01 | -0.10 |
| | N3 Time | -0.09 | -0.15, -0.03 | **0.004** | -0.07 | (-0.12, -0.02) | **0.007** | 86.8 | 0.72 | -1.15 | -0.08 |
| | WASO Time | -0.07 | -0.13, -0.01 | **0.037** | -0.07 | (-0.12, -0.02) | **0.006** | 78.6 | 0.74 | 21.00 | -0.07 |
| | Heart Rate | -13.08 | -44.72, 18.57 | 0.432 | – | – | – | 24.2 | 1.84 | 133.52 | 0 |
| Morning Sleep Opportunity | Blood CE | 11.33 | 6.39, 16.28 | **<0.000** | 10.84 | (5.98,15.71) | **<0.001** | 98.6 | 0.97 | -5.49 | 10.59 |
| | CSF CE | 132.86 | 101.23, 164.50 | **<0.000** | 140.28 | (113.86, 166.71) | **<0.001** | 100.0 | 1.04 | 1.82 | 135.82 |
| | Age | -0.81 | -1.47, -0.144 | **0.022** | -0.95 | (-1.55, -0.34) | **0.003** | 75.8 | 1.28 | 38.20 | -0.94 |
| | Male Sex | -4.27 | -7.73, -0.82 | **0.020** | -3.24 | (-5.93, -0.55) | **0.023** | 69.0 | 0.84 | 9.25 | -3.57 |
| | APOE ε4 | -13.22 | -23.65, -2.79 | **0.017** | -9.25 | (-13.20, -5.29) | **<0.001** | 92.6 | 1.06 | -13.49 | -9.74 |
| | $R_P$ | 38.06 | 7.87, 68.24 | **0.018** | 34.42 | (5.25, 63.59) | **0.025** | 65.4 | 0.81 | 20.18 | 37.42 |
| | REM Time | 0.58 | 0.10, 1.06 | **0.024** | 0.41 | (0.20, 0.62) | **<0.001** | 88.2 | 1.00 | -14.04 | 0.40 |
| | N1 Time | -0.28 | -0.59, 0.02 | 0.080 | -0.26 | (-0.50, -0.02) | **0.040** | 61.6 | 0.93 | 36.23 | -0.29 |
| | N2 Time | -0.11 | -0.24, 0.022 | 0.116 | -0.13 | (-0.26, -0.01) | 0.051 | 41.4 | 1.30 | 63.35 | 0 |
| | N3 Time | -0.18 | -0.37, 0.00 | 0.063 | -0.17 | (-0.33, -0.021) | **0.031** | 44.2 | 0.65 | 15.70 | 0 |
| | WASO Time | 0.19 | -0.10, 0.56 | 0.344 | – | – | – | 33.4 | 1.53 | 57.53 | 0 |
| | Heart Rate | -23.75 | -107.49, 59.98 | 0.591 | – | – | – | 18.2 | 2.01 | -28.96 | 0 |

1498 Electroencephalography, EEG; Parenchymal Resistance, $R_P$; Heart Rate, HR; Contrast Enhancement, CE; 95% Confidence Interval,
1499 CI; Backward Elimination, BE; Root-Mean Square Deviation, RMSD; within ROI variability, $\sigma^2$; inter-ROI variability, $\tau_{00\ ROI}$. **Bolded P**
1500 **values reflect significant associations at P < 0.05**. Shaded cells demark the **null model** that includes blood CE, CSF CE and
1501 potential biological confounders.
1502

**Supplemental Table 4. The change in parenchymal resistance resulting from large changes in EEG band power and heart rate during REM sleep, NREM sleep and wake for each study.**

| Study / Condition | Sleep Stage | Predictors | Fixed Effects | | | | Threshold Model Parameters | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | Estimate | CI | p | DF | Positive Threshold | Negative Threshold | Slope Ratio |
| Benchmarking Study / Overnight Sleep Op | REM | Δdelta | -0.42 | (-0.62, -0.21) | **<0.001** | 240 | 1.28 | -1.5 | 2 |
| | | Δtheta | -0.41 | (-0.91, 0.082) | 0.105 | 240 | 1.5 | -1.3 | 0.5 |
| | | Δalpha | -0.05 | (-0.21, 0.10) | 0.504 | 240 | 1.5 | -0.08 | 2 |
| | | Δbeta | 0.54 | (0.16, 0.91) | **0.006** | 240 | 1.5 | -1.35 | 0.5 |
| | | ΔHR | 0.10 | (-0.26, 0.47) | 0.588 | 202 | 1.5 | -0.9 | 0.5 |
| | NREM | Δdelta | -0.21 | (-0.46, 0.039) | 0.099 | 1038 | 1.5 | -1.5 | 0.95 |
| | | Δtheta | -0.12 | (-0.33, 0.090) | 0.263 | 1038 | 1.23 | -1.43 | 0.5 |
| | | Δalpha | -0.14 | (-0.30, 0.0063) | 0.061 | 1038 | 1.5 | -1.23 | 0.98 |
| | | Δbeta | 0.04 | (-0.039, 0.12) | 0.334 | 1038 | 1.3 | -1.5 | 2 |
| | | ΔHR | 0.13 | (0.014, 0.25) | **0.029** | 820 | 1.5 | -0.25 | 0.5 |
| Benchmarking Study / Overnight Sleep Deprivation | WAKE | Δdelta | -0.07 | (-0.18, 0.046) | 0.243 | 631 | 0.75 | 0 | 0.5 |
| | | Δtheta | -0.08 | (-0.17, 0.0084) | 0.076 | 631 | 0.73 | -1.5 | 2 |
| | | Δalpha | 0.07 | (-0.049, 0.19) | 0.245 | 631 | 1.5 | 0 | 0.5 |
| | | Δbeta | 0.05 | (-0.15, 0.26) | 0.601 | 631 | 1.5 | -1 | 0.83 |
| | | ΔHR | -0.10 | (-0.20, 0.0017) | 0.055 | 596 | 0.05 | 0 | 0.5 |
| Replication Study / Overnight Sleep Op | REM | Δdelta | -0.69 | (-1.1, -0.33) | **0.000** | 78 | 1.43 | -1.38 | 2 |
| | | Δtheta | -0.23 | (-0.39, -0.074) | **0.006** | 78 | 0.1 | -1.5 | 2 |
| | | Δalpha | -0.19 | (-0.46, 0.084) | 0.183 | 78 | 1.1 | -0.1 | 1.25 |
| | | Δbeta | 0.27 | (-0.13, 0.68) | 0.196 | 78 | 1.48 | -0.45 | 1.08 |
| | | ΔHR | 1.08 | (0.45, 1.7) | **0.001** | 68 | 1.5 | -1.23 | 0.9 |
| | NREM | Δdelta | -0.32 | (-0.57, -0.064) | **0.015** | 341 | 1.5 | -0.8 | 0.6 |
| | | Δtheta | 0.03 | (-0.043, 0.11) | 0.379 | 341 | 0 | -1.5 | 2 |
| | | Δalpha | 0.03 | (-0.049,0.11) | 0.482 | 341 | 0.03 | -1.5 | 2 |
| | | Δbeta | 0.13 | (0.045, 0.22) | **0.003** | 341 | 0.38 | -1.5 | 2 |
| | | ΔHR | 0.05 | (-0.14, 0.25) | 0.602 | 294 | 0.63 | -1.5 | 1.13 |
| Replication Study / Overnight Sleep Deprivation | WAKE | Δdelta | 0.04 | (-0.075, 0.16) | 0.479 | 505 | 0.8 | -1.5 | 2 |
| | | Δtheta | 0.03 | (-0.043, 0.096) | 0.460 | 505 | 0 | -1.5 | 2 |
| | | Δalpha | 0.09 | (-0.063, 0.25) | 0.247 | 505 | 1.15 | -1.5 | 2 |
| | | Δbeta | 0.18 | (0.031, 0.34) | **0.019** | 505 | 1.48 | -1.43 | 2 |
| | | ΔHR | -0.11 | (-0.27, 0.056) | 0.204 | 405 | 1 | -0.35 | 0.88 |

Rapid eye movement, REM; non-REM, NREM; Confidence Interval, CI; Degrees of Freedom, DF; EEG band power predictor units in percent of total band power; HR predictor units beats-per-minute. **Bolded P values reflect significant associations at P < 0.05**. Predictor and parenchymal resistance values in regression models were scaled to zero mean and unit standard deviation to simplify effect size comparisons across predictors. Positive and negative thresholds are in units of predictor standard deviation. Models included confounding biological variables age, gender, and APOE ε4 status.

1518 **Supplemental Table 5. The change in parenchymal resistance resulting from large**
1519 **changes in EEG band power and heart rate at NREM-REM and sleep-wake transitions for**
1520 **each study.**
1521

| Study | Transition | Predictors | Fixed Effects | | | | Threshold Model Parameters | | |
|---|---|---|---|---|---|---|---|---|---|
| | | | Estimate | CI | P | DF | Positive Threshold | Negative Threshold | Slope Ratio |
| Benchmarking Study | NREM to REM | Δalpha | 0.86 | (-0.05, 1.77) | 0.073 | 52 | 0.725 | -1.5 | 0.5 |
| | | Δbeta | 1.01 | (0.18, 1.85) | **0.023** | 52 | 0.35 | -1.5 | 0.5 |
| | | Δdelta | -0.31 | (-0.96, 0.34) | 0.359 | 52 | 1.5 | -1.15 | 2 |
| | | ΔHR | 0.10 | (-0.27, 0.47) | 0.593 | 37 | 1.5 | 0 | 2 |
| | | Δtheta | 0.28 | (-0.37, 0.93) | 0.405 | 52 | 0 | -1.5 | 0.5 |
| | REM to NREM | Δalpha | -0.17 | (-0.46, 0.13) | 0.276 | 45 | 1.5 | 0 | 2 |
| | | Δbeta | -0.08 | (-0.29, 0.13) | 0.445 | 45 | 0.2 | -1.5 | 1.9 |
| | | Δdelta | -0.43 | (-0.74, -0.11) | **0.011** | 45 | 1 | -0.9 | 2 |
| | | ΔHR | 0.32 | (-0.13, 0.78) | 0.180 | 34 | 1.5 | -0.625 | 2 |
| | | Δtheta | -0.03 | (-0.17, 0.1) | 0.628 | 45 | 0 | 0 | 2 |
| | Sleep to Wake | Δalpha | -0.89 | (-1.71, -0.08) | **0.038** | 53 | 0.775 | -1.5 | 0.5 |
| | | Δbeta | 0.67 | (-0.14, 1.47) | 0.114 | 53 | 0.35 | -1.5 | 0.5 |
| | | Δdelta | 0.03 | (-0.17, 0.23) | 0.778 | 53 | 0.025 | -1.45 | 2 |
| | | ΔHR | -0.32 | (-1.01, 0.38) | 0.383 | 39 | 0 | -1.4 | 0.5 |
| | | Δtheta | 0.04 | (-0.2, 0.29) | 0.737 | 53 | 0.25 | -1.5 | 1.75 |
| | Wake to Sleep | Δalpha | -0.31 | (-0.98, 0.37) | 0.377 | 89 | 1.5 | -0.975 | 0.525 |
| | | Δbeta | 0.45 | (-0.07, 0.96) | 0.095 | 89 | 1.5 | -1.25 | 2 |
| | | Δdelta | -0.22 | (-0.6, 0.17) | 0.273 | 89 | 0.2 | -1.5 | 0.9 |
| | | ΔHR | -0.11 | (-0.25, 0.03) | 0.145 | 64 | 0 | 0 | 2 |
| | | Δtheta | -0.20 | (-0.68, 0.27) | 0.409 | 89 | 0.05 | -1.3 | 0.5 |
| Replication Study | REM to NREM | Δalpha | 0.26 | (-0.46, 0.97) | 0.493 | 8 | 1.5 | -0.1 | 2 |
| | | Δbeta | -0.75 | (-2.45, 0.94) | 0.400 | 8 | 0.175 | -1.325 | 0.5 |
| | | Δdelta | 2.23 | (-0.7, 5.16) | 0.167 | 8 | 1.15 | -1.475 | 1.8 |
| | | ΔHR | -0.75 | (-2.21, 0.71) | 0.342 | 7 | 0.825 | -0.675 | 0.5 |
| | | Δtheta | 0.11 | (-0.73, 0.95) | 0.803 | 8 | 1.5 | -0.675 | 1.9 |
| | REM to NREM | Δalpha | -2.79 | (-5.55, -0.04) | 0.073 | 12 | 1.5 | -1.5 | 0.5 |
| | | Δbeta | 0.05 | (-0.4, 0.51) | 0.825 | 12 | 0.4 | -0.625 | 2 |
| | | Δdelta | -2.05 | (-4.21, 0.12) | 0.092 | 12 | 1.05 | -1.5 | 0.5 |
| | | ΔHR | -0.73 | (-6.16, 4.7) | 0.782 | 3 | 0.9 | -0.975 | 0.5 |
| | | Δtheta | -2.04 | (-2.97, -1.11) | **0.001** | 12 | 0.05 | -1.5 | 0.5 |
| | Wake to Sleep | Δalpha | 0.23 | (-0.5, 0.96) | 0.557 | 17 | 1.5 | -0.225 | 2 |
| | | Δbeta | 1.65 | (0.54, 2.76) | **0.011** | 17 | 0.1 | -1.5 | 0.5 |
| | | Δdelta | 2.55 | (-3.56, 8.66) | 0.436 | 17 | 1.425 | -1.5 | 0.5 |
| | | ΔHR | 0.36 | (-0.2, 0.91) | 0.236 | 17 | 1.5 | -0.025 | 2 |
| | | Δtheta | 0.03 | (-0.66, 0.73) | 0.931 | 17 | 1.5 | 0 | 2 |

Rapid eye movement, REM; non-REM, NREM; Confidence Interval, CI; Degrees of Freedom,
DF; EEG band power predictor units in percent of total band power; HR predictor units beats-
per-minute. **Bolded P values reflect significant associations at P < 0.05.** Predictor and
parenchymal resistance values in regression models were scaled to zero mean and unit
standard deviation with coefficient estimates representing effect size in standard deviations.
Positive and negative thresholds are in units of predictor standard deviation.

**Supplemental Table 6. Comparison of investigational device and polysomnography hypnogram staging to manual scoring.**

1529

| Manual Scoring | Device | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| | W | REM | N1 | N2 | N3 | | sensitivity | specificity | precision | accuracy | f1 |
| W | 2653 | 56 | 256 | 156 | 6 | | 0.828 | 0.959 | 0.843 | 0.932 | 0.835 |
| REM | 121 | 1334 | 130 | 127 | 2 | | 0.801 | 0.972 | 0.776 | 0.954 | 0.788 |
| N1 | 162 | 44 | 583 | 250 | 0 | | 0.367 | 0.967 | 0.558 | 0.905 | 0.443 |
| N2 | 224 | 224 | 611 | 4490 | 20 | | 0.774 | 0.886 | 0.804 | 0.844 | 0.789 |
| N3 | 7 | 5 | 2 | 753 | 877 | | 0.969 | 0.945 | 0.525 | 0.947 | 0.681 |
| | PSG C3 | | | | | | | | | | |
| | W | REM | N1 | N2 | N3 | | sensitivity | specificity | precision | accuracy | f1 |
| W | 2922 | 56 | 68 | 79 | 2 | | 0.892 | 0.981 | 0.928 | 0.962 | 0.910 |
| REM | 40 | 1563 | 37 | 74 | 0 | | 0.893 | 0.989 | 0.910 | 0.978 | 0.901 |
| N1 | 178 | 54 | 467 | 339 | 1 | | 0.707 | 0.961 | 0.447 | 0.950 | 0.547 |
| N2 | 94 | 76 | 85 | 5188 | 126 | | 0.870 | 0.958 | 0.929 | 0.924 | 0.899 |
| N3 | 4 | 0 | 1 | 262 | 1377 | | 0.914 | 0.979 | 0.825 | 0.973 | 0.867 |
| | PSG C4 | | | | | | | | | | |
| | W | REM | N1 | N2 | N3 | | sensitivity | specificity | precision | accuracy | f1 |
| W | 3035 | 22 | 31 | 39 | 0 | | 0.974 | 0.991 | 0.964 | 0.987 | 0.969 |
| REM | 3 | 1665 | 21 | 25 | 0 | | 0.965 | 0.996 | 0.969 | 0.993 | 0.967 |
| N1 | 27 | 20 | 659 | 333 | 0 | | 0.885 | 0.974 | 0.631 | 0.969 | 0.736 |
| N2 | 10 | 12 | 32 | 5493 | 22 | | 0.913 | 0.990 | 0.984 | 0.960 | 0.947 |
| N3 | 0 | 5 | 0 | 104 | 1535 | | 0.985 | 0.990 | 0.920 | 0.990 | 0.951 |

1530 Polysomnography, PSG; Wake, W; Rapid eye movement, REM

1531 **Supplemental Table 7: Electrode characterization according to ANSI/AAMI EC12*.**

1532

| Electrode Pair # | AC Impedance at 10 Hz [Ω] | DC Offset Voltage [mV] | Combined Offset Instability and Internal Noise [µV] | | Bias Current Tolerance [mV] |
|---|---|---|---|---|---|
| | | | EC12 (0.15-100 Hz) | EEG (0.3-50 Hz) | |
| 1 | 609 | 0.5 | 22.9 | 9.7 | 11.2 |
| 2 | 759 | 0.3 | 126.4 | 28.2 | 10.7 |
| 3 | 1023 | 3.8 | 13.3 | 7.9 | 10.8 |
| 4 | 1035 | 1.4 | 19.6 | 8.0 | 7.0 |
| 5 | 583 | 1.4 | 7.1 | 1.9 | 9.5 |
| 6 | 424 | 1.1 | 8.1 | 3.8 | 9.3 |

1533 Alternating Current, AC; Direct Current, DC; EC12, ANSI/AAMI EC12:2000/(R)2020.

1534    *ANSI/AAMI EC12 reference values are as follows: AC impedance under 3000 Ω in any pair, under 2000 Ω on average; DC offset
1535    under 100 mV; offset instability and internal noise under 150 μV; tolerance to bias under 100 mV.
1536
1537

1538 **Supplemental Table 8. Benchtop tests for assessing calibration and sensivity to electrode impedance.**

1539

| | Setting | Electrode Configuration | | | | Load | Measured Load Components |
| | | Left | | Right | | | |
| | | MASTOID | IN-EAR | IN-EAR | MASTOID | [Ω] | Measured [Ω] |
|---|---|---|---|---|---|---|---|
| | Cal R 20 | Low | Low | Low | Low | 20 | 20.0 |
| | Cal R 40 | Low | Low | Low | Low | 40.2 | 40.2 |
| | Cal R 60 | Low | Low | Low | Low | 60.4 | 60.3 |
| | Cal R 80 | Low | Low | Low | Low | 80.6 | 80.5 |
| | Cal R 100 | Low | Low | Low | Low | 100 | 100.4 |
| Calibration 2R1C | Cal 2R1C 20 | Low | Low | Low | Low | 20\|(470 + 22n) | Rs = 20, Rp=468.2, Cp = 23.3n |
| | Cal 2R1C 40 | Low | Low | Low | Low | 40.2\|(470 + 22n) | Rs = 40.2, Rp=468.2, Cp = 23.3n |
| | Cal 2R1C 60 | Low | Low | Low | Low | 60.4\|(470 + 22n) | Rs = 60.3, Rp=468.2, Cp = 23.3n |
| | Cal 2R1C 80 | Low | Low | Low | Low | 80.6\|(470 + 22n) | Rs = 80.5, Rp=468.2, Cp = 23.3n |
| | Cal 2R1C 100 | Low | Low | Low | Low | 100\|(470 + 22n) | Rs = 100.4, Rp=468.2, Cp = 23.3n |
| Sensitivity to Electrode Impedance | Low All | Low | Low | Low | Low | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Right Mastoid | Low | Low | Low | High | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Right | Low | Low | High | High | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Right In-Ear | Low | Low | High | Low | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High In-Ear | Low | High | High | Low | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Left In-Ear | Low | High | Low | Low | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Left | High | High | Low | Low | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Left Mastoid | High | Low | Low | Low | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High Mastoids | High | Low | Low | High | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |
| | High All | High | High | High | High | 50\|(470 + 22n) | Rs = 49.9, Rp=468.2, Cp = 23.3n |

　　　　　　Element to change from one benchtop test to the next

1540

1541 **Supplemental Table 9. Absolute error of resistance for benchtop tests (values in ohms).**

| | Setting | 1kHz | 1.6kHz | 2.28kHz | 3.2kHz | 4.55kHz | 6.4kHz | 8.53kHz | 12.8kHz | 16kHz | 25.6kHz | 32kHz | 51.2kHz | 64kHz | 85.3kHz | 102kHz | 128kHz |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calibration R | Cal R 20 | 0.125 | 0.151 | 0.157 | 0.119 | 0.127 | 0.154 | 0.182 | 0.190 | 0.220 | 0.308 | 0.320 | 0.274 | 0.094 | 0.379 | 0.700 | 0.702 |
| | Cal R 40 | 0.220 | 0.161 | 0.152 | 0.192 | 0.221 | 0.094 | 0.164 | 0.117 | 0.127 | 0.151 | 0.200 | 0.301 | 0.134 | 0.438 | 0.344 | 0.396 |
| | Cal R 60 | 0.333 | 0.231 | 0.325 | 0.307 | 0.301 | 0.413 | 0.411 | 0.208 | 0.308 | 0.326 | 0.276 | 0.456 | 0.327 | 0.412 | 0.268 | 0.301 |
| | Cal R 80 | 0.104 | 0.175 | 0.242 | 0.205 | 0.314 | 0.140 | 0.154 | 0.257 | 0.258 | 0.332 | 0.333 | 0.257 | 0.284 | 0.298 | 0.317 | 0.230 |
| | Cal R 100 | 0.301 | 0.288 | 0.268 | 0.251 | 0.261 | 0.323 | 0.236 | 0.271 | 0.458 | 0.380 | 0.199 | 0.157 | 0.387 | 0.324 | 0.196 | 0.134 |
| Calibration 2R1C | Cal 2R1C 20 | 0.232 | 0.277 | 0.244 | 0.105 | 0.130 | 0.125 | 0.141 | 0.087 | 0.211 | 0.247 | 0.383 | 0.355 | 0.228 | 0.371 | 0.522 | 0.756 |
| | Cal 2R1C 40 | 0.191 | 0.117 | 0.112 | 0.305 | 0.207 | 0.042 | 0.207 | 0.149 | 0.268 | 0.157 | 0.134 | 0.240 | 0.314 | 0.242 | 0.421 | 0.311 |
| | Cal 2R1C 60 | 0.372 | 0.213 | 0.356 | 0.292 | 0.202 | 0.209 | 0.263 | 0.276 | 0.333 | 0.475 | 0.260 | 0.301 | 0.522 | 0.434 | 0.380 | 0.318 |
| | Cal 2R1C 80 | 0.215 | 0.166 | 0.249 | 0.175 | 0.186 | 0.252 | 0.231 | 0.168 | 0.348 | 0.384 | 0.303 | 0.211 | 0.333 | 0.331 | 0.280 | 0.143 |
| | Cal 2R1C 100 | 0.384 | 0.304 | 0.256 | 0.295 | 0.195 | 0.159 | 0.294 | 0.283 | 0.428 | 0.423 | 0.339 | 0.379 | 0.208 | 0.172 | 0.193 | 0.021 |
| Sensitivity to Electrode Impedance | Low All | 0.284 | 0.159 | 0.181 | 0.318 | 0.227 | 0.171 | 0.280 | 0.263 | 0.136 | 0.152 | 0.165 | 0.279 | 0.237 | 0.192 | 0.454 | 0.330 |
| | High Right Mastoid | 0.123 | 0.003 | 0.165 | 0.220 | 0.176 | 0.210 | 0.071 | 0.120 | 0.128 | 0.085 | 0.001 | 0.300 | 0.242 | 0.650 | 0.362 | 0.725 |
| | High Right | 0.131 | 0.242 | 0.079 | 0.279 | 0.232 | 0.253 | 0.274 | 0.144 | 0.202 | 0.186 | 0.167 | -0.022 | 0.383 | 0.586 | 0.620 | 0.911 |
| | High Right In-Ear | 0.259 | 0.256 | 0.249 | 0.297 | 0.252 | 0.347 | 0.183 | 0.182 | 0.279 | 0.256 | 0.212 | 0.315 | 0.139 | 0.529 | 0.457 | 0.576 |
| | High In-Ear | 0.384 | 0.263 | 0.109 | 0.233 | 0.350 | 0.236 | 0.237 | 0.292 | 0.266 | 0.259 | 0.312 | 0.327 | 0.379 | 0.415 | 0.446 | 0.450 |
| | High Left In-Ear | 0.210 | 0.169 | 0.236 | 0.313 | 0.262 | 0.319 | 0.229 | 0.269 | 0.280 | 0.332 | 0.324 | 0.168 | 0.303 | 0.255 | 0.361 | 0.310 |
| | High Left | 0.266 | 0.337 | 0.372 | 0.241 | 0.271 | 0.281 | 0.252 | 0.167 | 0.388 | 0.501 | 0.416 | 0.266 | 0.128 | 0.225 | 0.218 | 0.006 |
| | High Left Mastoid | 0.341 | 0.325 | 0.217 | 0.225 | 0.222 | 0.193 | 0.185 | 0.242 | 0.430 | 0.363 | 0.269 | 0.242 | 0.143 | 0.097 | 0.268 | 0.018 |
| | High Mastoids | 0.307 | 0.227 | 0.235 | 0.364 | 0.286 | 0.192 | 0.348 | 0.363 | 0.339 | 0.277 | 0.238 | 0.146 | 0.498 | 0.455 | 0.492 | 0.487 |
| | High All | 0.517 | 0.412 | 0.447 | 0.374 | 0.418 | 0.420 | 0.342 | 0.397 | 0.425 | 0.461 | 0.375 | 0.418 | 0.527 | 0.727 | 0.852 | 0.843 |

1542
1543

**Supplemental Table 10. Absolute error of reactance for benchtop tests (values in ohms).**

| | Setting | 1kHz | 1.6kHz | 2.28kHz | 3.2kHz | 4.55kHz | 6.4kHz | 8.53kHz | 12.8kHz | 16kHz | 25.6kHz | 32kHz | 51.2kHz | 64kHz | 85.3kHz | 102kHz | 128kHz |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Calibration R** | **Cal R 20** | 0.087 | -0.031 | 0.055 | -0.046 | 0.010 | -0.016 | 0.104 | -0.030 | 0.142 | 0.237 | 0.172 | 0.188 | 0.018 | 0.250 | 0.197 | 0.288 |
| | **Cal R 40** | 0.032 | 0.042 | 0.011 | 0.055 | -0.054 | -0.057 | 0.126 | 0.035 | 0.018 | -0.027 | 0.027 | 0.087 | -0.070 | 0.057 | 0.102 | 0.040 |
| | **Cal R 60** | 0.103 | 0.007 | -0.025 | 0.070 | -0.052 | -0.017 | 0.025 | 0.044 | 0.069 | -0.071 | 0.090 | -0.041 | -0.032 | -0.129 | -0.050 | -0.107 |
| | **Cal R 80** | 0.036 | 0.073 | 0.015 | -0.132 | -0.042 | 0.064 | 0.012 | -0.010 | 0.047 | 0.072 | 0.040 | -0.010 | -0.061 | -0.092 | -0.162 | -0.181 |
| | **Cal R 100** | -0.066 | -0.054 | 0.028 | -0.019 | 0.011 | 0.153 | 0.057 | -0.051 | -0.002 | 0.022 | 0.045 | -0.003 | -0.133 | -0.024 | -0.050 | -0.121 |
| **Calibration 2R1C** | **Cal 2R1C 20** | 0.044 | -0.039 | -0.037 | 0.019 | 0.043 | 0.033 | 0.031 | 0.051 | 0.091 | 0.143 | 0.210 | 0.211 | 0.237 | 0.285 | 0.413 | 0.380 |
| | **Cal 2R1C 40** | 0.001 | -0.070 | -0.029 | 0.084 | -0.049 | 0.030 | -0.050 | -0.033 | 0.026 | 0.000 | -0.008 | 0.020 | 0.117 | 0.074 | 0.097 | 0.114 |
| | **Cal 2R1C 60** | 0.019 | 0.006 | -0.043 | -0.017 | 0.009 | 0.032 | 0.120 | -0.120 | -0.005 | 0.034 | -0.149 | 0.089 | 0.106 | 0.041 | 0.204 | 0.122 |
| | **Cal 2R1C 80** | 0.095 | -0.005 | 0.018 | 0.145 | -0.018 | -0.073 | 0.001 | 0.017 | 0.013 | 0.010 | 0.145 | 0.058 | 0.076 | -0.012 | -0.028 | 0.104 |
| | **Cal 2R1C 100** | -0.030 | -0.118 | -0.014 | 0.065 | -0.066 | 0.025 | 0.070 | 0.055 | 0.074 | 0.037 | 0.174 | 0.158 | 0.012 | 0.092 | 0.041 | 0.105 |
| **Sensitivity to Electrode Impedance** | **Low All** | 0.015 | -0.066 | 0.047 | -0.052 | 0.046 | 0.016 | 0.068 | -0.040 | -0.032 | -0.112 | 0.006 | 0.107 | 0.121 | 0.006 | 0.093 | 0.112 |
| | **High Right Mastoid** | 0.113 | 0.084 | 0.030 | 0.095 | 0.131 | -0.034 | 0.043 | 0.043 | 0.103 | 0.139 | 0.160 | 0.251 | 0.309 | 0.388 | 0.389 | 0.306 |
| | **High Right** | 0.029 | 0.059 | -0.024 | 0.159 | 0.000 | 0.098 | 0.028 | 0.016 | 0.059 | 0.124 | 0.186 | 0.136 | 0.243 | 0.204 | 0.459 | 0.335 |
| | **High Right In-Ear** | 0.015 | -0.074 | -0.001 | -0.019 | 0.073 | 0.044 | 0.076 | 0.042 | 0.011 | 0.073 | 0.047 | 0.131 | 0.123 | -0.009 | 0.150 | 0.133 |
| | **High In-Ear** | 0.071 | -0.015 | 0.000 | -0.074 | 0.026 | -0.104 | -0.007 | 0.028 | 0.087 | 0.045 | 0.021 | 0.103 | 0.203 | 0.111 | 0.043 | 0.160 |
| | **High Left In-Ear** | -0.007 | 0.001 | 0.015 | 0.013 | -0.042 | -0.168 | 0.045 | 0.010 | -0.049 | 0.006 | -0.032 | 0.038 | 0.237 | 0.150 | 0.070 | 0.137 |
| | **High Left** | -0.150 | -0.117 | -0.154 | -0.178 | 0.012 | -0.104 | -0.025 | -0.124 | -0.172 | -0.159 | -0.127 | -0.253 | -0.173 | -0.147 | -0.124 | -0.099 |
| | **High Left Mastoid** | -0.173 | -0.093 | -0.169 | -0.045 | -0.104 | -0.073 | 0.001 | -0.104 | -0.032 | -0.211 | -0.271 | -0.187 | -0.212 | -0.076 | -0.251 | -0.091 |
| | **High Mastoids** | 0.034 | -0.002 | 0.036 | -0.023 | -0.100 | -0.010 | -0.054 | 0.032 | -0.042 | -0.103 | 0.008 | -0.006 | 0.083 | 0.082 | 0.176 | 0.058 |
| | **High All** | -0.041 | -0.114 | -0.083 | -0.109 | -0.091 | -0.066 | -0.051 | 0.065 | 0.083 | 0.103 | 0.013 | 0.138 | 0.278 | 0.296 | 0.389 | 0.401 |

1549

1550 **Supplemental Table 11. Debye model absolute prediction error (ohms) of dispersion relative to 128kHz.**

1551

| | Setting | 1kHz | 1.6kHz | 2.28kHz | 3.2kHz | 4.55kHz | 6.4kHz | 8.53kHz | 12.8kHz | 16kHz | 25.6kHz | 32kHz | 51.2kHz | 64kHz | 85.3kHz | 102kHz |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | **Low All** | -0.037 | -0.040 | -0.044 | -0.051 | -0.063 | -0.080 | -0.093 | -0.098 | -0.091 | -0.058 | -0.042 | -0.017 | -0.010 | -0.004 | -0.002 |
| | **High Right Mastoid** | -0.243 | -0.250 | -0.260 | -0.278 | -0.309 | -0.345 | -0.368 | -0.352 | -0.311 | -0.187 | -0.133 | -0.054 | -0.032 | -0.014 | -0.006 |
| | **High Right** | -0.247 | -0.252 | -0.261 | -0.277 | -0.302 | -0.332 | -0.350 | -0.331 | -0.291 | -0.175 | -0.124 | -0.050 | -0.030 | -0.013 | -0.006 |
| | **High Right In-Ear** | -0.109 | -0.113 | -0.120 | -0.132 | -0.152 | -0.178 | -0.197 | -0.197 | -0.177 | -0.110 | -0.079 | -0.032 | -0.019 | -0.008 | -0.004 |
| Sensitivity to Electrode Impedance | **High In-Ear** | -0.128 | -0.130 | -0.134 | -0.140 | -0.150 | -0.162 | -0.168 | -0.158 | -0.139 | -0.084 | -0.060 | -0.024 | -0.015 | -0.006 | -0.003 |
| | **High Left In-Ear** | -0.055 | -0.053 | -0.051 | -0.046 | -0.039 | -0.027 | -0.015 | 0.000 | 0.005 | 0.007 | 0.006 | 0.003 | 0.002 | 0.001 | 0.000 |
| | **High Left** | 0.065 | 0.069 | 0.074 | 0.082 | 0.098 | 0.119 | 0.136 | 0.144 | 0.133 | 0.087 | 0.063 | 0.026 | 0.016 | 0.007 | 0.003 |
| | **High Left Mastoid** | 0.067 | 0.070 | 0.075 | 0.084 | 0.099 | 0.118 | 0.135 | 0.142 | 0.131 | 0.085 | 0.062 | 0.026 | 0.015 | 0.007 | 0.003 |
| | **High Mastoids** | -0.119 | -0.120 | -0.121 | -0.124 | -0.127 | -0.131 | -0.130 | -0.116 | -0.100 | -0.059 | -0.042 | -0.017 | -0.010 | -0.004 | -0.002 |
| | **High All** | -0.202 | -0.209 | -0.221 | -0.240 | -0.271 | -0.311 | -0.338 | -0.329 | -0.293 | -0.178 | -0.127 | -0.052 | -0.031 | -0.013 | -0.006 |

| | 1kHz | 1.6kHz | 2.28kHz | 3.2kHz | 4.55kHz | 6.4kHz | 8.53kHz | 12.8kHz | 16kHz | 25.6kHz | 32kHz | 51.2kHz | 64kHz | 85.3kHz | 102kHz |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **RMSE** | 0.147 | 0.151 | 0.157 | 0.168 | 0.186 | 0.209 | 0.224 | 0.216 | 0.193 | 0.117 | 0.084 | 0.034 | 0.020 | 0.009 | 0.004 |
| **Load Value** | 4.766 | 4.724 | 4.654 | 4.526 | 4.282 | 3.877 | 3.374 | 2.461 | 1.931 | 0.995 | 0.685 | 0.286 | 0.183 | 0.099 | 0.066 |
| **Error %** | 3.1% | 3.2% | 3.4% | 3.7% | 4.3% | 5.4% | 6.6% | 8.8% | 10.0% | 11.8% | 12.2% | 12.0% | 11.1% | 8.8% | 6.1% |

1552

1553 **Supplemental Table 12: Minimum significant change in mean $R_p$ and correlation with a**
1554 **predictor using the $R_p$ standard deviation of the electrode impedance sensitivity tests.**
1555

| Number of Samples | 25 | 100 |
|---|---|---|
| Standard Deviation [Ω] | 0.113 | 0.113 |
| Standard Error [Ω] | 0.023 | 0.011 |
| Minimum Significant Change [Ω] | 0.044 | 0.022 |
| Minimum Significant Correlation | 0.39 | 0.20 |

1556 Brain parenchymal resistance, $R_p$.
1557
1558

1559

1560
1561
**Supplemental Figure 1.** An illustration of the effect of increased CSF influx into the brain
parenchyma and clearance from the parenchyma on contrast-enhanced MRI signal intensity in
the Benchmarking study. An increase in CSF influx into the brain parenchyma following
intravenous GBCA leads to greater contrast delivery to the brain parenchyma and a
corresponding increase in MRI signal intensity. MRI signal intensity of the brain parenchyma
has been shown to peak at approximately 90 minutes post-injection[15] which occurred at time
0830 in the Benchmarking study. With a terminal half-life of 109 minutes[28], intravenous contrast
is 60% cleared at 140 minutes post-injection when the morning sleep/wake intervention begins
and is 80% cleared at the end of the morning intervention when the second post-contrast MRI
scan is acquired. During this morning intervention, an increase in CSF clearance from the brain
parenchyma leads to a corresponding decrease in MRI signal intensity.

**Supplemental Figure 2.**

**a**

**b**

**Electrode Models**

|  | $R_{HF}$ | $R_{LF}$ | $C_{LF}$ |
|---|---|---|---|
| **Low** | 270 | 1k | 180n |
| **High** | 620 | 3.3k | 82n |

**c**

**Load Models**

|  | $R_s$ | $R_p$ | $C_p$ |
|---|---|---|---|
| **Cal Loads** | 0-100 | -/470 | -/22n |
| **Realistic Load** | 50* | 470 | 22n |

*  50 realized with a 49.9 ohm resistor

1574

**Supplemental Figure 2. a,** Circuit model of transcranial measurements using four-point
electrical impedance spectroscopy and models for each of the four electrode contact
impedances. **b**, Electrode impedance models comprised a low impedance and a high
impedance model, representing the range of in-human impedances. **c**, Calibration loads varied
the resistance **R$_s$** of the free fluid or interstitial fluid compartment from 20 to 100 Ω in increments
of 20 Ω, with and additional $R_pC_p$ in parallel to simulate complex loads. The realistic load
parameters were chosen to create a frequency dispersion that approximated the in-human
measured dispersions. **d**, Electrode impedance dispersion over the measured frequencies for
the low and high impedance model. **e**, Load impedance dispersion over the measured
frequencies using the Real Load model.

1585

1586    **Supplemental Figure 3.**

1587
1588
1589    **Supplemental Figure 3. a**, Periodogram of a device over a 12 hour test using four Ag/AgCl
1590    sintered disk electrodes on an Agar phantom with EEG gel. For reference, human EEG beta
1591    power during NREM sleep is above -10dB on the device. **b**, EEG recording over an epoch
1592    shows 0.5 µV peak-to-peak noise. **c**, Power spectral density shows a noise floor at
1593    -150dB/Hz with a 1/f increase to -140db/Hz below 10Hz.
1594

**REFERENCES**

1. Iliff, J. J. *et al.* A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. *Sci Transl Med* **4**, 147ra111 (2012). https://doi.org/10.1126/scitranslmed.3003748

2. Xie, L. *et al.* Sleep drives metabolite clearance from the adult brain. *Science* **342**, 373-377 (2013). https://doi.org/10.1126/science.1241224

3. Iliff, J. J. *et al.* Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. *J Neurosci* **34**, 16180-16193 (2014). https://doi.org/10.1523/JNEUROSCI.3020-14.2014

4. Harrison, I. F. *et al.* Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. *Brain* **143**, 2576-2593 (2020). https://doi.org/10.1093/brain/awaa179

5. Ishida, K. *et al.* Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration. *J Exp Med* **219** (2022). https://doi.org/10.1084/jem.20211275

6. Cui, H. *et al.* Decreased AQP4 Expression Aggravates α-Synuclein Pathology in Parkinson's Disease Mice, Possibly via Impaired Glymphatic Clearance. *J Mol Neurosci* **71**, 2500-2513 (2021). https://doi.org/10.1007/s12031-021-01836-4

7. Zou, W. *et al.* Blocking meningeal lymphatic drainage aggravates Parkinson's disease-like pathology in mice overexpressing mutated α-synuclein. *Transl Neurodegener* **8**, 7 (2019). https://doi.org/10.1186/s40035-019-0147-y

8. Hablitz, L. M. & Nedergaard, M. The Glymphatic System: A Novel Component of Fundamental Neurobiology. *J Neurosci* **41**, 7698-7711 (2021). https://doi.org/10.1523/JNEUROSCI.0619-21.2021

9. Klostranec, J. M. *et al.* Current Concepts in Intracranial Interstitial Fluid Transport and the Glymphatic System: Part II-Imaging Techniques and Clinical Applications. *Radiology* **301**, 516-532 (2021). https://doi.org/10.1148/radiol.2021204088

10. Hablitz, L. M. *et al.* Circadian control of brain glymphatic and lymphatic fluid flow. *Nat Commun* **11**, 4411 (2020). https://doi.org/10.1038/s41467-020-18115-2

11. Hablitz, L. M. *et al.* Increased glymphatic influx is correlated with high EEG delta power and low heart rate in mice under anesthesia. *Sci Adv* **5**, eaav5447 (2019). https://doi.org/10.1126/sciadv.aav5447

12. Eide, P. K., Vinje, V., Pripp, A. H., Mardal, K. A. & Ringstad, G. Sleep deprivation impairs molecular clearance from the human brain. *Brain* **144**, 863-874 (2021). https://doi.org/10.1093/brain/awaa443

13. Ringstad, G. *et al.* Brain-wide glymphatic enhancement and clearance in humans assessed with MRI. *JCI Insight* **3** (2018). https://doi.org/10.1172/jci.insight.121537

14. Deike-Hofmann, K. *et al.* Glymphatic Pathway of Gadolinium-Based Contrast Agents Through the Brain: Overlooked and Misinterpreted. *Invest Radiol* **54**, 229-237 (2019). https://doi.org/10.1097/RLI.0000000000000533

15. Richmond, S. B. *et al.* Quantification approaches for magnetic resonance imaging following intravenous gadolinium injection: A window into brain-wide glymphatic function. *Eur J Neurosci* **57**, 1689-1704 (2023). https://doi.org/10.1111/ejn.15974

16. Bera, T. K. Bioelectrical Impedance Methods for Noninvasive Health Monitoring: A Review. *J Med Eng* **2014**, 381251 (2014). https://doi.org/10.1155/2014/381251

17. Abasi, S., Aggas, J. R., Garayar-Leyva, G. G., Walther, B. K. & Guiseppi-Elie, A. Bioelectrical Impedance Spectroscopy for Monitoring Mammalian Cells and Tissues

1641   under Different Frequency Domains: A Review. *ACS Meas Sci Au* **2**, 495-516 (2022).
1642   https://doi.org/10.1021/acsmeasuresciau.2c00033

1643 18 Stupin, D. D. *et al.* Bioimpedance Spectroscopy: Basics and Applications. *ACS Biomater*
1644   *Sci Eng* **7**, 1962-1986 (2021). https://doi.org/10.1021/acsbiomaterials.0c01570

1645 19 Gabriel, S., Lau, R. W. & Gabriel, C. The dielectric properties of biological tissues: II.
1646   Measurements in the frequency range 10 Hz to 20 GHz. *Phys Med Biol* **41**, 2251-2269
1647   (1996). https://doi.org/10.1088/0031-9155/41/11/002

1648 20 Gabriel, C. Dielectric properties of biological tissue: variation with age.
1649   *Bioelectromagnetics* **Suppl 7**, S12-18 (2005). https://doi.org/10.1002/bem.20147

1650 21 Jessen, N. A., Munk, A. S., Lundgaard, I. & Nedergaard, M. The Glymphatic System: A
1651   Beginner's Guide. *Neurochem Res* **40**, 2583-2599 (2015). https://doi.org/10.1007/s11064-
1652   015-1581-6

1653 22 Nakamura, K. *et al.* Diurnal fluctuations in brain volume: Statistical analyses of MRI
1654   from large populations. *Neuroimage* **118**, 126-132 (2015).
1655   https://doi.org/10.1016/j.neuroimage.2015.05.077

1656 23 Elvsåshagen, T. *et al.* Cerebral blood flow changes after a day of wake, sleep, and sleep
1657   deprivation. *Neuroimage* **186**, 497-509 (2019).
1658   https://doi.org/10.1016/j.neuroimage.2018.11.032

1659 24 Dagum, P. Non-invasive assessment of glymphatic flow and neurodegeneration from a
1660   wearable device. (**2022**).

1661 25 Dagum, P. Non-invasive assessment of glymphatic flow and neurodegeneration from a
1662   wearable device. (2022).

1663 26 Nasreddine, Z. S. *et al.* The Montreal Cognitive Assessment, MoCA: a brief screening
1664   tool for mild cognitive impairment. *J Am Geriatr Soc* **53**, 695-699 (2005).
1665   https://doi.org/10.1111/j.1532-5415.2005.53221.x

1666 27 Brown, L. M. & Schinka, J. A. Development and initial validation of a 15-item informant
1667   version of the Geriatric Depression Scale. *Int J Geriatr Psychiatry* **20**, 911-918 (2005).
1668   https://doi.org/10.1002/gps.1375

1669 28 Administration., U. F. a. D. *Gadavist (gadobutrol) injection, for intravenous use*,
1670   <https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201277s000lbl.pdf>
1671   (2011).

1672 29 Heinze, G., Wallisch, C. & Dunkler, D. Variable selection - A review and
1673   recommendations for the practicing statistician. *Biom J* **60**, 431-449 (2018).
1674   https://doi.org/10.1002/bimj.201700067

1675 30 Iliff, J. J. *et al.* Brain-wide pathway for waste clearance captured by contrast-enhanced
1676   MRI. *J Clin Invest* **123**, 1299-1309 (2013). https://doi.org/10.1172/JCI67677

1677 31 Boukamp, B. A. A Linear Kronig-Kramers Transform Test for Immittance Data
1678   Validation. *Journal of The Electrochemical Society* **142**, 1885 (1995).

1679 32 Schonleber, M., Klotz, D. & Ivers-Tiffee, E. A Method for Improving the Robustness of
1680   linear Kramers-Kronig Validity Tests. *Electrochimica Acta* **131**, 20-27 (2014).

1681 33 Song, J. *et al.* Electrical Impedance Changes at Different Phases of Cerebral Edema in
1682   Rats with Ischemic Brain Injury. *Biomed Res Int* **2018**, 9765174 (2018).
1683   https://doi.org/10.1155/2018/9765174

1684 34 Abboud, T., Mielke, D. & Rohde, V. Mini Review: Impedance Measurement in
1685   Neuroscience and Its Prospective Application in the Field of Surgical Neurooncology.
1686   *Front Neurol* **12**, 825012 (2021). https://doi.org/10.3389/fneur.2021.825012

35    Witkowska-Wrobel, A., Aristovich, K., Crawford, A., Perkins, J. D. & Holder, D.
Imaging of focal seizures with Electrical Impedance Tomography and depth electrodes in
real time. *Neuroimage* **234**, 117972 (2021).
https://doi.org/10.1016/j.neuroimage.2021.117972
36    Romsauerova, A. *et al.* Multi-frequency electrical impedance tomography (EIT) of the
adult human head: initial findings in brain tumours, arteriovenous malformations and
chronic stroke, development of an analysis method and calibration. *Physiol Meas* **27**,
S147-161 (2006). https://doi.org/10.1088/0967-3334/27/5/S13
37    Iliff, J. J. *et al.* Cerebral arterial pulsation drives paravascular CSF-interstitial fluid
exchange in the murine brain. *J Neurosci* **33**, 18190-18199 (2013).
https://doi.org/10.1523/JNEUROSCI.1592-13.2013
38    Ringstad, G., Vatnehol, S. A. S. & Eide, P. K. Glymphatic MRI in idiopathic normal
pressure hydrocephalus. *Brain* **140**, 2691-2705 (2017).
https://doi.org/10.1093/brain/awx191
39    Mestre, H. *et al.* Aquaporin-4-dependent glymphatic solute transport in the rodent brain.
*Elife* **7** (2018). https://doi.org/10.7554/eLife.40070
40    Mestre, H. *et al.* Flow of cerebrospinal fluid is driven by arterial pulsations and is
reduced in hypertension. *Nat Commun* **9**, 4878 (2018). https://doi.org/10.1038/s41467-
018-07318-3
41    Jiang-Xie, L. F. *et al.* Neuronal dynamics direct cerebrospinal fluid perfusion and brain
clearance. *Nature* **627**, 157-164 (2024). https://doi.org/10.1038/s41586-024-07108-6
42    Piantino, J., Lim, M. M., Newgard, C. D. & Iliff, J. Linking Traumatic Brain Injury,
Sleep Disruption and Post-Traumatic Headache: a Potential Role for Glymphatic
Pathway Dysfunction. *Curr Pain Headache Rep* **23**, 62 (2019).
https://doi.org/10.1007/s11916-019-0799-4
43    Nedergaard, M. & Goldman, S. A. Glymphatic failure as a final common pathway to
dementia. *Science* **370**, 50-56 (2020). https://doi.org/10.1126/science.abb8739
44    Goldman, N., Hablitz, L. M., Mori, Y. & Nedergaard, M. The Glymphatic System and
Pain. *Med Acupunct* **32**, 373-376 (2020). https://doi.org/10.1089/acu.2020.1489
45    Braun, M. & Iliff, J. J. The impact of neurovascular, blood-brain barrier, and glymphatic
dysfunction in neurodegenerative and metabolic diseases. *Int Rev Neurobiol* **154**, 413-
436 (2020). https://doi.org/10.1016/bs.irn.2020.02.006
46    Gakuba, C. *et al.* General Anesthesia Inhibits the Activity of the "Glymphatic System".
*Theranostics* **8**, 710-722 (2018). https://doi.org/10.7150/thno.19154
47    Miao, A. *et al.* Brain clearance is reduced during sleep and anesthesia. *Nat Neurosci* **27**,
1046-1050 (2024). https://doi.org/10.1038/s41593-024-01638-y
48    Kress, B. T. *et al.* Impairment of paravascular clearance pathways in the aging brain. *Ann
Neurol* **76**, 845-861 (2014). https://doi.org/10.1002/ana.24271
49    Wang, M. *et al.* Focal Solute Trapping and Global Glymphatic Pathway Impairment in a
Murine Model of Multiple Microinfarcts. *J Neurosci* **37**, 2870-2877 (2017).
https://doi.org/10.1523/JNEUROSCI.2112-16.2017
50    Li, M. *et al.* Impaired Glymphatic Function and Pulsation Alterations in a Mouse Model
of Vascular Cognitive Impairment. *Front Aging Neurosci* **13**, 788519 (2021).
https://doi.org/10.3389/fnagi.2021.788519

51   Xu, Z. *et al.* Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ
accumulation and memory deficits. *Mol Neurodegener* **10**, 58 (2015).
https://doi.org/10.1186/s13024-015-0056-1
52   Simon, M. *et al.* Loss of perivascular aquaporin-4 localization impairs glymphatic
exchange and promotes amyloid β plaque formation in mice. *Alzheimers Res Ther* **14**, 59
(2022). https://doi.org/10.1186/s13195-022-00999-5
53   Pedersen, T. J., Keil, S. A., Han, W., Wang, M. X. & Iliff, J. J. The effect of aquaporin-4
mis-localization on Aβ deposition in mice. *Neurobiol Dis* **181**, 106100 (2023).
https://doi.org/10.1016/j.nbd.2023.106100
54   Burfeind, K. G. *et al.* The effects of noncoding aquaporin-4 single-nucleotide
polymorphisms on cognition and functional progression of Alzheimer's disease.
*Alzheimers Dement (N Y)* **3**, 348-359 (2017). https://doi.org/10.1016/j.trci.2017.05.001
55   Zeppenfeld, D. M. *et al.* Association of Perivascular Localization of Aquaporin-4 With
Cognition and Alzheimer Disease in Aging Brains. *JAMA Neurol* **74**, 91-99 (2017).
https://doi.org/10.1001/jamaneurol.2016.4370
56   Simon, M. J. *et al.* Transcriptional network analysis of human astrocytic endfoot genes
reveals region-specific associations with dementia status and tau pathology. *Sci Rep* **8**,
12389 (2018). https://doi.org/10.1038/s41598-018-30779-x
57   Instrumentation, A. N. S. I. A. f. A. o. M.  Vol. EC12:2000/(R)2020   (2020).
58   Ayllon, D., Seoane, F. & Gil-Pita, R. Cole equation and parameter estimation from
electrical bioimpedance spectroscopy measurements - A comparative study. *Annu Int
Conf IEEE Eng Med Biol Soc* **2009**, 3779-3782 (2009).
https://doi.org/10.1109/IEMBS.2009.5334494
59   De Lorenzo, A., Andreoli, A., Matthie, J. & Withers, P. Predicting body cell mass with
bioimpedance by using theoretical methods: a technological review. *J Appl Physiol
(1985)* **82**, 1542-1558 (1997). https://doi.org/10.1152/jappl.1997.82.5.1542
60   Gabriel, S., Lau, R. W. & Gabriel, C. The dielectric properties of biological tissues: III.
Parametric models for the dielectric spectrum of tissues. *Phys Med Biol* **41**, 2271-2293
(1996). https://doi.org/10.1088/0031-9155/41/11/003
61   Welch, P. The use of the fast Fourier transform for the estimation of power spectra: A
method based on time averaging over short, modified periodograms. *IEEE Trans. Audio
Electroacoust* **15**, 70-73 (1967).
62   Vallat, R. & Walker, M. P. An open-source, high-performance tool for automated sleep
staging. *Elife* **10** (2021). https://doi.org/10.7554/eLife.70092
63   Quinn, A. J., Lopes-Dos-Santos, V., Dupret, D., Nobre, A. C. & Woolrich, M. W. EMD:
Empirical Mode Decomposition and Hilbert-Huang Spectral Analyses in Python. *J Open
Source Softw* **6** (2021). https://doi.org/10.21105/joss.02977
64   Heart rate variability: standards of measurement, physiological interpretation and clinical
use. Task Force of the European Society of Cardiology and the North American Society
of Pacing and Electrophysiology. *Circulation* **93**, 1043-1065 (1996).
65   Janelidze, S. *et al.* Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in
Alzheimer Disease. *JAMA Neurol* **78**, 1375-1382 (2021).
https://doi.org/10.1001/jamaneurol.2021.3180
66   Roberts, K. F. *et al.* Amyloid-β efflux from the central nervous system into the plasma.
*Ann Neurol* **76**, 837-844 (2014). https://doi.org/10.1002/ana.24270

67 Liu, H. *et al.* Acute sleep loss decreases CSF-to-blood clearance of Alzheimer's disease
biomarkers. *Alzheimers Dement* (2023). https://doi.org/10.1002/alz.12930
68 Loh, S., Lamond, N., Dorrian, J., Roach, G. & Dawson, D. The validity of psychomotor
vigilance tasks of less than 10-minute duration. *Behav Res Methods Instrum Comput* **36**,
339-346 (2004). https://doi.org/10.3758/bf03195580
69 Arsintescu, L. *et al.* Validation of a touchscreen psychomotor vigilance task. *Accid Anal*
*Prev* **126**, 173-176 (2019). https://doi.org/10.1016/j.aap.2017.11.041
70 Arbuthnott, K. & Frank, J. Trail making test, part B as a measure of executive control:
validation using a set-switching paradigm. *J Clin Exp Neuropsychol* **22**, 518-528 (2000).
https://doi.org/10.1076/1380-3395(200008)22:4;1-0;FT518
71 *Digit Span (DGS)*, <https://cambridgecognition.com/digit-span-dgs/> (
72 *PVT Research Tool*, <https://apps.apple.com/tr/app/pvt-research-tool/id1475726298> (
73 Smith, A. *Symbol Digit Modalities Test*. (Western Psychological Association, 1992).
74 Reitan, R. *Trail Making Test: Manual for Administration and Scoring*. (1992).
75 Diagnostics, C. N. <https://c2n.com/> (
76 Piantino, J. *et al.* Link between Mild Traumatic Brain Injury, Poor Sleep, and Magnetic
Resonance Imaging: Visible Perivascular Spaces in Veterans. *J Neurotrauma* **38**, 2391-
2399 (2021). https://doi.org/10.1089/neu.2020.7447
77 Boespflug, E. L. *et al.* MR Imaging-based Multimodal Autoidentification of Perivascular
Spaces (mMAPS): Automated Morphologic Segmentation of Enlarged Perivascular
Spaces at Clinical Field Strength. *Radiology* **286**, 632-642 (2018).
https://doi.org/10.1148/radiol.2017170205
78 Levendovszky, S. R. *et al.* Preliminary cross-sectional investigations into the human
glymphatic system using multiple novel non-contrast MRI methods. *bioRxiv* (2023).
https://doi.org/10.1101/2023.08.28.555150
79 Ohene, Y. *et al.* Non-invasive MRI of brain clearance pathways using multiple echo time
arterial spin labelling: an aquaporin-4 study. *Neuroimage* **188**, 515-523 (2019).
https://doi.org/10.1016/j.neuroimage.2018.12.026
80 Fultz, N. E. *et al.* Coupled electrophysiological, hemodynamic, and cerebrospinal fluid
oscillations in human sleep. *Science* **366**, 628-631 (2019).
https://doi.org/10.1126/science.aax5440
81 Fong, Y., Huang, Y., Gilbert, P. B. & Permar, S. R. chngpt: threshold regression model
estimation and inference. *BMC Bioinformatics* **18**, 454 (2017).
https://doi.org/10.1186/s12859-017-1863-x
82 Fong, Y., Di, C. & Permar, S. Change point testing in logistic regression models with
interaction term. *Stat Med* **34**, 1483-1494 (2015). https://doi.org/10.1002/sim.6419
83 Farokhian, F., Yang, C., Beheshti, I., Matsuda, H. & Wu, S. Age-Related Gray and White
Matter Changes in Normal Adult Brains. *Aging Dis* **8**, 899-909 (2017).
https://doi.org/10.14336/AD.2017.0502
84 Ding, F. *et al.* Changes in the composition of brain interstitial ions control the sleep-wake
cycle. *Science* **352**, 550-555 (2016). https://doi.org/10.1126/science.aad4821
85 Sun, Y. & Sun, X. Exploring the interstitial system in the brain: the last mile of drug
delivery. *Rev Neurosci* **32**, 363-377 (2021). https://doi.org/10.1515/revneuro-2020-0057
86 Hotelling, H. New light on the correlation coefficient and its transforms. *Journal of the*
*Royal Statistical Society. Series B (Methodological)* **15.2**, 193-232 (1953).
1821